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Summary 
 
 
Epithelial-to-Mesenchymal Transition (EMT) is a reversible trans-differentiation 
process that confers to cancer cells several traits required for malignant progression and 
metastatization.  
In this thesis I report that the silencing of the RNA-binding protein KHSRP, 
mediated by the microRNA miR-27b-3p, is required for Transforming Growth Factor β 
(TGF-β)-induced EMT in mammary gland cells. We found that sustained KHSRP 
expression limits TGF-β-dependent induction of EMT factors and cell migration, 
whereas its knockdown in untreated cells mimics TGF-β-induced EMT. Genome-wide 
sequencing analyses revealed that KHSRP affects the expression of select genes at two 
distinct post-transcriptional levels by controlling: 
1. the levels of mature miR-192-5p (a microRNA that targets a group of EMT factors); 
2. the alternative splicing of a cohort of microRNA precursors related to cell adhesion 
and motility including CD44, ENAH and FGFR2.  
KHSRP belongs to a ribonucleoprotein complex that includes hnRNPA1, and 
the two proteins cooperate in promoting epithelial-type exon usage of select pre-mRNAs. 
The importance of the KHSRP/hnRNPA1 complex in regulating the alternative splicing 
of factors critical to cell adhesion and migration is highlighted by the fact that Resveratrol 
(RESV), a natural polyphenolic compound, increases the expression of both KHSRP and 
hnRNPA1. We also show that, as a consequence of KHSRP and hnRNPA1 increased 
expression, RESV counteracts the TGF-β-induced EMT phenotype in mammary gland 
cells and affects the alternative exon usage of pre-mRNAs that encode crucial factors in 
adhesion and migration (including CD44, ENAH, and FGFR2) in a panel of immortalized 
and transformed mammary gland cells. RESV causes a shift from the mesenchymal-
specific forms of these factors to the respective epithelial forms and the combined 
silencing of KHSRP and hnRNPA1 prevents the RESV-dependent inclusion of the 
epithelial-type exons in the Cd44 pre-mRNA.  
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In conclusion, our findings support the evidence that KHSRP plays a central 
role in the complex process that leads to the changes induced by TGF-β in mammary 
gland cells. 
 
 
 
Image modified from: Puppo et al., 2016 
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Abbreviation List 
 
 
Abbrevation Definition 
3’ UTR 3’ Untranslated Region 
ACTA2 Actin 
AKT RAC-serine/threonine-protein kinase 
ARE AU-rich element 
ARE-BP ARE-binding protein 
AS Alternative Splicing 
ATM ATM serine-protein kinase 
BMP Bone Morphogenetic Protein 
BRF1 Butyrate Response Factor 1 
CDH1 Cadherin 1 
CDH2 Cadherin 2 
Cdk1 Cyclin-dependent kinase 1 
CPM Count Per Million 
CSC Cancer Stem Cell 
DEXSeq Differential Exon usage 
Dis3 Ribonuclease chromosome Disjunction 3 
DSP Desmoplakin 
ECM Extracellular matrix 
EGF Epidermal Growth Factor 
ELAVL1 ELAV-like protein 1 
EMT Epithelial-to-Mesenchymal Transition 
ERK Extracellular signal-regulated kinase 
ESRP1 Epithelial Splicing Regulatory proteins 1 
ESRP2 Epithelial Splicing Regulatory proteins 2 
FGFR FGF-Receptor 
FN1 Fibronectin 
FSTL1 Follistatin-like 1 
GAP43 Growth Associated Protein 43 
Gly Glycine 
GO Gene ontology 
GSK-3β Glycogen Synthase Kinase-3 β 
hnRNP Heterogeneous nuclear Ribonucleoprotein Particle 
JNK c-Jun N-terminal kinase 
KH domain Heterogeneous nuclear ribonucleoprotein K homology domain 
KHSRP KH-type Splicing Regulatory Protein 
LIN28 Protein lin-28 homolog A 
lncRNA Long non-coding RNA 
MAPK14 p38 mitogen-activated protein kinase 
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MET Mesenchymal-to-Epithelial Transition 
miRNA MicroRNA 
MMP Matrix Metalloproteinase 
Myog Myogenin 
NF-κB Nuclear Factor-κB 
NMP Nucleophosmin 
NOS2 Nitric Oxide Synthase 2 
OCLN Occludin 
ORF Open reading frame 
PARN poly(A)-Rnase 
PDGF Platelet Derived Growth Factor 
Per2 Period Circadian Clock 2 
PI3K Phosphatidyl Inositol 3-Kinase 
PRC2 Polycomb repressor complex 2 
pre-miRNA Precursor microRNA 
pri-miRNA Primary microRNA 
RESV Resveratrol 
RIP Ribonucleoprotein Immunoprecipitation 
RISC RNA-Induced Silencing Complex 
RNA Pol II RNA polymerase II 
RNA-seq RNA sequencing 
RPB RNA-binding protein 
RT-qPCR Retro Transcription- quantitative Polymerase Chain Reaction 
Ser Serine 
SIRT1 Sirtuin-1 
TGF-β Transforming Growth Factor β 
Thr Threonine 
TL Terminal loop 
TNF Tumor Necrosis Factor 
TRIM33 Tripartite Motif Containing 33 
TTP Tristetraprolin 
UTRN Utrophin 
VIM Vimentin 
VTN Vitronectin 
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Introduction 
 
 
EPITHELIAL-TO-MESENCHYMAL TRANSITION 
 
Epithelial-to-Mesenchymal Transition (EMT) is a reversible trans-differentiation 
program that plays a central role in both physiological and pathological processes, such 
as embryogenesis, development, wound healing, fibrosis, and tumor progression (Thiery, 
2003; Kalluri & Weinberg, 2009; Lim & Thiery, 2012; Jolly et al, 2017). During EMT 
process, a polarized epithelial cell undergoes multiple biochemical changes and acquires a 
mesenchymal phenotype which includes enhanced migratory capacity, invasiveness, 
elevated resistance to apoptosis, increased production of extracellular matrix (ECM) 
components as well as the potential to enter a stem cell-like state (Kalluri & Neilson, 2003; 
De Craene & Berx, 2013; Ye & Weinberg, 2015).  
 
The concept of EMT emerged many years ago from initial observations that 
both embryonic and adult epithelial cells have the potential to convert to fibroblast-like 
cells with migratory and invasive properties in 3D collagen gels (Greenburg & Hay, 1982). 
EMT has been classified into three different subtypes (Figure 1) based on the 
biological contexts in which it occurs (Kalluri & Weinberg, 2009): 
 Type I: associated with implantation, embryo formation, and organ development; 
 Type II: associated with wound healing, tissue regeneration, organ fibrosis, and 
the presence of inflammation; 
 Type III: associated with cancer progression in which neoplastic cells invade other 
tissues and metastasize. 
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Figure 1; Different types of EMT processes (Scanlon et al, 2013). 
 
EMT is reversible and the opposite trans-differentiation process is called 
Mesenchymal-to-Epithelial Transition (MET) (De Craene & Berx, 2013; Ye & Weinberg, 
2015). In tumor progression, cancer cells undergo EMT to escape from the primary 
tumor, invade adjacent tissues, intravasate in blood or lymphatic vessels, travel through 
the circulation system, extravasate, and finally colonize distant organs to form metastasis 
(Tam & Weinberg, 2013). In the last step, cells that had acquired mesenchymal features 
can revert to the epithelial state through MET (Tam & Weinberg, 2013) (Figure 2). 
 
 
Figure 2; EMT and MET processes during metastasis formation (Tam & Weinberg, 2013). 
10 
 
The contribution of EMT to cancer cell invasion and metastasis has been well 
documented in many types of carcinoma, and clinical evidence support the idea that high-
grade tumors associated to poor prognosis often contain cells that express molecular 
signatures of EMT (Tam & Weinberg, 2013). However, some tumors contain neoplastic 
cells that, even if have acquired mesenchymal markers, retained certain epithelial 
characteristics showing a ‘partial EMT’ (Sarrió et al, 2008; Grigore et al, 2016). Sometimes 
cells enter an intermediate state where mesenchymal and epithelial features coexist, and 
in some cases (e.g. the absence of pro-EMT signals) they may naturally revert to an 
epithelial state (Tam & Weinberg, 2013). The idea that ‘partial EMT’ refers to an 
intermediate state between EMT and MET has been recently changed with the concept 
of a stable hybrid Epithelial/Mesenchymal phenotype (Jolly et al, 2015). Moreover, the 
connection between carcinoma cells that have undergone EMT and the acquisition of 
stem-like properties have been described extensively in multiple tumor types, and cells 
that have only undergone a ‘partial EMT’ have more chances to acquire stem-like 
properties, while several studies have reported that in certain tumors the mesenchymal 
cells, after completing the EMT program, lack the ability to behave as stem cells (Prieto-
Garcìa et al, 2017; Grosse-Wilde et al, 2015; Jolly et al, 2015; Andriani et al, 2016). 
Although EMT is commonly believed to contribute to metastasis, two recent 
studies challenged this idea suggesting that EMT is instead a prerequisite for acquisition 
of chemoresistance (Fischer et al, 2015; Zheng et al, 2015). Fischer and colleagues 
engineered cancer cell in order to track reversible EMT in vivo and showed that EMT is 
not required for metastasis, whereas it confers chemoresistance to cancer cells (Fischer et 
al, 2015). In addition, Zheng and colleagues demonstrated that suppression of EMT leads 
to enhanced expression of nucleoside transporters in tumors, contributing to enhanced 
sensitivity to gemcitabine treatment and increased overall survival of mice (Zheng et al, 
2015). Nonetheless, the two alternative views can be reconciled and it is possible to 
propose that pro-metastatic properties of EMT may originate from its ability to induce 
chemoresistance enabling cells to survive therapeutics and cause metastasis (Qi et al, 
2016). The above described debates highlight the concept that EMT is not a stereotypical 
program and various versions of this process are expressed under different conditions in 
a variety of carcinomas (Pattabiraman & Weinberg, 2016). 
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The conversion from an epithelial to a mesenchymal cell requires changes in cell 
morphology and cell/matrix adhesion as well as the acquisition of migratory abilities 
(Prieto-Garcìa et al, 2017). Phenotypical hallmarks of EMT include morphological 
changes from a cobblestone-like epithelial shape to a spindle-like fibroblast phenotype, 
loss of epithelial Cadherin 1 (CDH1; also known as E-Cadherin) expression at cell 
junctions, decreased expression of the desmosome protein Desmoplakin (DSP) as well as 
the tight junction protein Occludin (OCLN), with increased expression of mesenchymal 
Cadherin 2 (CDH2; also known as N-Cadherin), Vimentin (VIM) and Matrix 
Metalloproteinases (MMPs) (Kalluri & Neilson, 2003; Kalluri & Weinberg, 2009; Lee et 
al, 2006; Nieto et al, 2016). A group of EMT-inducing transcription factors, including 
SNAI1, SNAI2, ZEB1, ZEB2, TWIST1, and TWIST2, are activated during EMT and co-
operate in orchestrating the molecular changes (Kalluri & Weinberg, 2009; Nieto et al, 
2016). Some of the transcripts whose expression is modified during EMT are listed in 
Figure 3.  
 
 
Figure 3; Factors involved in EMT (Kalluri & Weinberg, 2009). 
 
The expression of CDH1 at the cell surface contributes to maintain intact 
cell/cell interactions and stabilizes the cytoskeleton preventing cell mobility, whereas its 
downregulation causes adherents junctions breakdown leading to a mesenchymal 
phenotype with migratory abilities (Tam & Weinberg, 2013; Prieto-Garcìa et al, 2017). 
CDH1 down-regulation and inactivation of the Cdh1 gene have been described during 
tumor cell progression (Acs et al, 2001; Guilford et al, 1998; Pharoah et al, 2001). It has 
been reported that Cdh1 transcription is repressed by transcription factors such as SNAI1, 
SNAI2, ZEB1, ZEB2, TWIST1 and TWIST2, Homeobox proteins (GSC and SIX1), 
bHLH factor E2.2 (TCF4), and Forkhead-Box protein (FOXC2) (Bolos et al, 2003; Canel 
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et al, 2013; Serrano-Gomez et al, 2016). Additional genes encoding tight junction proteins 
(e.g. Claudins and OCLNs) are subject to transcriptional repression, thus allowing tumor 
invasiveness (Ikenouchi et al, 2003; Martinez-Estrada et al, 2006). 
SNAI1/2 proteins have a central role in EMT determining overexpression of 
mesenchymal markers such as Fibronectin (FN1) and Vitronectin (VTN), and 
suppression of various epithelial markers (Zeisberg & Neilson, 2009). SNAI1 is also 
known to upregulate the expression of several MMP genes including MMP9 which 
degrades the basement membrane stimulating tumor cell invasion (Kessenbrock et al, 
2010). In addition, SNAI1 blocks cell-cycle progression, contributes to cell survival, and 
regulates the expression of genes related to the apoptosis pathway (Scanlon et al, 2013). 
Further, SNAI1 and SNAI2 are involved in the acquisition of stem-like traits (Zeisberg & 
Neilson, 2009; Kurrey et al, 2009). As a critical regulator of multiple signaling pathways 
leading to EMT, the expression of SNAI1 is closely associated with cancer metastasis 
(Wang et al, 2013). 
TWIST1/2 proteins modulate the expression of many target genes through E-
box-responsive elements (Scanlon et al, 2013). The two TWIST genes, Twist1 and Twist 2, 
are well-conserved in Vertebrates, and TWIST1/2 proteins can act as either 
transcriptional repressors of epithelial markers, such as CDH1, or activators of 
mesenchymal markers, such as CDH2 and FN1 (Scanlon et al, 2013).  Like SNAI1, 
TWIST1/2 proteins are upregulated in many cancer (Zeisberg & Neilson, 2009).  
Also epigenetic regulation and post-translational modification can regulate EMT 
process (Prieto-Garcìa et al, 2017; Serrano-Gomez et al, 2016; Nieto et al, 2016). It has 
been demonstrated that EMT program is activated by epigenetic regulation (e.g. 
modification of histone tails, global hypomethylation of genome, and specific 
hypermethylation of cytosine residues in CpG islands in the DNA promoter regions) that 
either promotes or represses the expression of EMT-related genes (Prieto-Garcìa et al, 
2017; Kouzarides, 2007). Post-translational modifications involved in EMT program 
include acetylation, methylation, phosphorylation, ubiquitination, sumoylation, proline 
isomerization, and deamination (Serrano-Gomez et al, 2016). For example, SNAI1 
expression is controlled by Glycogen Synthase Kinase-3 β (GSK-3β) phosphorylation that 
regulates its ubiquitination and its subcellular localization: the inhibition of GSK-3β 
causes SNAI1 upregulation and can induce the EMT program (Zhou et al, 2004). 
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 Various signals that cells receive from their microenvironment can initiate the 
EMT process (Teng et al, 2007; Kalluri & Weinberg, 2009; Polyak & Weinberg, 2009; 
Nisticò et al, 2012; Nieto et al, 2016). In the context of the natural history of carcinoma 
cells important extracellular signals like WNT, NOTCH, and Transforming Growth 
Factor β (TGF-β) modulate EMT (Tam & Weinberg, 2013).   
TGF-β is considered to act as a primary inducer of EMT via activation of the 
SMAD family of transcription factors (Moustakas & Heldin, 2012; Ikushima & Miyazono, 
2010; Katsuno et al, 2013). TGF-β belongs to a large family of structurally related factors, 
including Activins and Bone Morphogenetic Proteins (BMPs), which regulate cell growth, 
survival, differentiation, and migration (Shi & Massagué, 2003). TGF-β is structurally 
characterized by a specific three-dimensional fold and by a conserved number and spacing 
of cysteine residues in the C-terminus of the mature polypeptide (Derynck & Miyazono, 
2008). All TGF-β ligands bind to Type I (seven in humans) and Type II (five in humans) 
Receptors (TGF-βRI and TGF-βRII, respectively) to generate heterotetrameric 
complexes in the presence of the dimeric ligand that transmit biological information into 
the cells (Wrana et al, 2008). Both types of receptors are characterized by a dual specificity 
cytoplasmic kinase domain: a strong serine/threonine (Ser/Thr) kinase activity and a 
weaker tyrosine (Tyr) kinase activity (Dijke & Heldin, 2006). Phosphorylation of TGF-
βRI by the Ser/Thr kinase activity of TGF-βRII creates a docking site in the Gly/Ser 
(GS)–rich domain of TGF-βRI that recruits, and consequently phosphorylates, the 
transcription factors SMAD2 and SMAD3 (Gonzalez & Medici, 2014). Phosphorylated 
SMADs form a complex with the common SMAD4 which then translocate into the 
nucleus to regulate gene expression by modulating gene transcription as well as promoting 
maturation of select microRNAs (miRNAs) from precursors (Tam & Weinberg, 2014; 
Blahna & Hata, 2012) (Figure 4). In addition to SMAD-dependent signaling, TGF-β 
receptor complexes are involved in a number of SMAD-independent pathways (Gonzalez 
& Medici, 2014). TGF-β can directly activate the Phosphatidyl Inositol 3-Kinase (PI3K) 
machinery through its own receptors or can trans-activate Epidermal Growth Factor 
(EGF) and Platelet Derived Growth Factor (PDGF) receptors (Gonzalez & Medici, 
2014). Moreover, TGF-β is a potent activator of various other kinase pathways including 
extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 
mitogen-activated protein kinase (MAPK14), whose activation can be SMAD-dependent 
or SMAD-independent (Gonzalez & Medici, 2014). 
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Figure 4; The complex network of TGF-β signaling in EMT (Gonzalez & Medici, 2014). 
 
Whereas in normal epithelial cells TGF-β suppresses cell proliferation, in the 
advanced stages of cancer TGF-β signaling is commonly hyper-activated and promotes 
invasion and metastasis (Kim et al, 2007; Saitoh, 2015). TGF-β can promote tumor 
progression by modifying tumor microenvironment since it regulates cell viability and 
function of immune cells, endothelial cells, and fibroblasts, as well as facilitates 
proliferation and motile properties of tumor cells (Bierie & Moses, 2006). Further, TGF-
β can cooperate with other growth factors in the cancer microenvironment (Tam & 
Weinberg, 2014; Ehata et al, 2007). Hence, TGF-β signaling inhibition has the potential 
to block EMT induction and, therefore, disease progression (Tam & Weinberg, 2014).  
TGF-β signaling can control also the epigenetic regulation of downstream target 
genes (Tam & Weinberg, 2014). SMAD2 and SMAD3 can associate with epigenetic 
regulators, such as Tripartite Motif Containing 33 (TRIM33), and cell exposure to TGF-
β increases the amount of the H3K4me3 and H3K36me3 chromatin marks (Xi et al, 2011; 
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McDonald et al, 2011). Experimental evidences suggest that TGF-β signaling can 
indirectly affect the alternative splicing of a number of mRNAs by regulating the 
expression of splicing factors (Tripathi et al, 2016; Horiguchi et al, 2012; Saitoh, 2015). 
For example, it has been demonstrated that TGF-β downregulates the expression of the 
Epithelial Splicing Regulatory proteins 1 (ESRP1) and 2 (ESRP2) that bind directly the 
FGF-Receptor (FGFR) mRNA and subsequently switches the epithelial IIIb isoforms of 
FGFRs to mesenchymal IIIc isoforms (Horiguchi et al, 2012). Importantly, aggressive 
breast cancer cells express only IIIc isoforms of FGFR, whereas non-aggressive cells 
express IIIb isoforms (Horiguchi et al, 2012). 
In the laboratory where I conducted my thesis, it has been demonstrated that 
the single-strand RNA binding protein KHSRP is a component of the TGF-β/BMP 
signaling pathway in multipotent mesenchymal C2C12 cells (Pasero et al, 2012). TGF-
β/BMP-activated SMAD proteins associate with KHSRP and block its ability to promote 
maturation of myogenic miRNAs from precursors, thus orienting C2C12 cells toward 
osteoblastic differentiation (Pasero et al, 2012). Accordingly, KHSRP silencing in C2C12 
cells produces effects that largely coincide with those induced by TGF-β/BMP signaling 
activation (Pasero et al, 2012). Further, it has been recently reported that TGF-β regulates 
wound healing by controlling KHSRP levels and determining a switch between miR-198 
and Follistatin-like 1 (FSTL1) protein expression (Sundaram et al, 2013). The human 
exonic miR-198 belongs to the protein-coding Fstl1 gene and it is expressed in normal 
epidermis, while upon injury, its levels early plummet and remain low for at least 24 hours 
after wounding (Tan et al, 2011; Sundaram et al, 2013). In contrast to miR-198, Fstl1 
mRNA and FSTL1 protein are expressed in the wound-edge epidermis 24 hours after 
injury, but not in normal epidermis (Sundaram et al, 2013). It has been shown that 
KHSRP has an essential role in miR-198/FSTL1 expression-switch since the processing 
of miR-198 is dependent on its trans-action (Sundaram et al, 2013). Sundaram and 
colleagues have demonstrated that KHSRP is physiologically expressed in normal 
epidermis but, upon injury, TGF-β1 downregulates its expression with the consequent 
switch-off of miR-198 expression and the promotion of FSTL1 expression (Sundaram et 
al, 2013). 
I will describe in detail the structure and the functions of KHSRP in the 
following section. 
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KHSRP, A MULTIFUNCIONAL PROTEIN 
 
KHSRP (KH-type Splicing Regulatory Protein, also known as KSRP or FBP2) 
is a single-stranded nucleic acid-binding protein independently discovered by the Levens 
and Black laboratories (Briata et al, 2016). KHSRP is ubiquitous and its 
nucleo/cytoplasmic distribution varies in distinct cell types (Gherzi et al, 2014). 
 
KHSRP was initially described as a factor interacting with an enhancer element 
upstream of the c-myc oncogene promoter, as a component of a multi-protein complex 
that binds to a splicing enhancer element of c-src pre-mRNA, and as part of the 
Apolipoprotein-B editing complex (Davis-Smyth et al, 1996; Min et al, 1997; Lellek et al, 
2000). Upon these initial discoveries, additional roles of KHSRP in the post-
transcriptional control of gene expression have been investigated in greater detail, 
specifically two distinct functions (Gherzi et al, 2014): 
1. the ability to favor degradation of labile mRNAs via AU-rich element (ARE)-
mediated decay; 
2. the ability to promote maturation from precursors of select miRNAs.  
In general, KHSRP is considered a regulator of gene expression that can 
modulates diverse cellular functions including cell differentiation/proliferation, innate 
immunity, and lipid metabolism (Briata et al, 2016). 
 
1. KHSRP STRUCTURE  
 
The Khsrp gene maps to human chromosome 19p13.3 and to mouse 
chromosome 17 (Ring et al., 1999). The human KHSRP protein has a length of 711 amino 
acids and a mass weigh of 73115 Dalton (data from UNIProtDataBase, 2017). KHSRP 
protein is organized in three distinct regions: a mainly structured central region that 
includes four KH domains (KH1 to 4) responsible for nucleic acid binding, and two low 
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complexity terminal regions that contain several sites for post-translational modifications 
as well as protein-interaction motifs (Gherzi et al., 2010) (Figure 5). 
 
 
Figure 5; Solution structure of KH4 domain of KHSRP (from http://www.rcsb.org/pdb/protein/Q92945). 
 
The heterogeneous nuclear ribonucleoprotein K (hnRNPK) homology (KH) 
domain, first identified in the hnRNPK protein, consists of approximately 70 amino acids 
and it has been recognized as a nucleic acid recognition motifs able to bind RNA or single-
strand DNA with varying degrees of affinity and specificity (Valverde et al., 2008). KH 
domains are found in multiple copies which can function independently or cooperatively 
(Valverde et al., 2008). They are present in proteins with various cellular functions 
including transcriptional and translational regulation (Chen & Varani, 2013). Interestingly, 
several diseases (e.g. Fragile X Mental Retardation Syndrome, Paraneoplastic Disease and 
some cancers) are associated with the loss of function of the KH domain (Valverde et al., 
2008). Analysis of available spatial structures revealed that two different KH domains, 
Type I and Type II, exist (Valverde et al., 2008). They belong to different protein folds, but 
share a single KH motif (βααβ): in addition to the motif core, Type I KH domains (e.g. 
hnRNPK) contain C-terminal extension βα and Type II KH-domains (e.g. ribosomal 
protein S3) include N-terminal extension αβ (Grishin, 2001) (Figure 6).  The Type I fold is 
typically found in eukaryotic proteins, whereas the Type II fold is typically found in 
prokaryotic proteins (Grishin, 2001). The highly conserved ‘GXXG loop’ of the KH 
domain directly interacts with the nucleobases of either DNA or RNA targets to make 
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specific contacts with protein moieties (Lewis et al., 2000). The KH domain can recognize 
specifically up to four nucleobases: of these, the nucleobases in positions 2 and 3 are 
normally recognized with a higher degree of specificity by moieties from the protein side 
chains (for position 2) and backbone (for position 3) (Hollingworth et al., 2012). Along 
with the interaction with the KH domain canonical recognition surface, the nucleic acid 
molecule can make non-specific contacts with protein groups outside the groove 
(Braddock et al., 2002).  
 
 
Figure 6; Structure of Type I and Type II KH domains (Valverde et al., 2008). 
 
The solution structure of the four KH domains of KHSRP has been solved and 
it was shown that the KH1 and KH4 can re-orient freely in solution respect to a central 
core formed by KH2 and KH3 thus allowing the protein to adapt to the structural context 
of different protein-RNA regulatory particles (García-Mayoral et al., 2008; Dìaz-Moreno 
et al., 2010). The RNA-binding specificity of each KH-domains of KHSRP has been 
established by Scaffold Independent Analysis (SIA), and the different specificities of the 
domains of KHSRP as well as their affinity for the AREs (‘UAUUUA’ and ‘UAUUAU’) 
have been extensively explored (García-Mayoral et al., 2008). More recently, it has been 
found that individual KH domains of KHSRP have different sequence specificities (Briata 
et al., 2013). While KH1, KH2 and KH4 bind to a broad range of sequences within a 
small range of affinities, KH3 interacts with a set of G-rich sequences, with an unusual 
affinity that is 100-fold higher than the affinity for AU-rich targets (García-Mayoral et al., 
2008). Importantly, the in vitro interaction of KHSRP with the RNA target is 
combinatorial, with each KH domain providing a fraction of the RNA binding affinity 
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(Hollingworth et al., 2012). Indeed, the Kd of isolated domains in complex with short 
AREs (derived from the target TNF-AREs) ranges between 10-4 and 10-3 M, while the Kd 
of the whole protein for the full TNF-AREs is 5 orders of magnitude lower (~4x10-9 M) 
(Hollingworth et al., 2012). KHSRP is also able to interact with high affinity with the 
terminal loop (TL) of both primary and precursor of miR-let-7a as well as of other 
miRNA precursors (Trabucchi et al, 2009). Structural and biophysical analyses revealed 
that the contribution of KH3 to KHSRP/miR-let-7a precursor interaction is 50 fold 
higher than the one provided by KH2 and KH4 (Nicastro et al., 2012). Further, NMR 
analysis of the interaction confirms that KH3 defines the binding frame of KHSRP on 
the miRNA precursors TL (Díaz-Moreno et al., 2009).  
Proteins, including RNA-binding proteins (RBPs), are often subject to post-
translational modifications like phosphorylation, which is a mechanism used by cells to 
link extracellular signals to different gene regulation pathways (Brivanlou & Darnell, 2002; 
Wilson et al., 2003; Gherzi et al., 2014). Two different signaling pathways, MAPK14 and 
the RAC-serine/threonine-protein kinase (AKT; also known as PKB) have been shown 
to target decay-promoting ARE-BPs including Tristetraprolin (TTP), Butyrate Response 
Factor 1 (BRF1), and KHSRP (Sandler & Stoecklin, 2008; Schmidlin et al., 2004; Ruggiero 
et al., 2007). KHSRP function is regulated by a number of post-translational modifications 
including phosphorylation by AKT on Ser 193, by ATM serine-protein kinase (ATM) on 
Ser 132, Ser 274 and Ser 670, and by MAPK14 on Thr 692 (Gherzi et al., 2006; Briata et 
al., 2005; Zhang et al., 2011) (Figure 10). 
 
 
Figure 10; Schematic representation of phosphorylation sites on KHSRP (Briata et al., 2005). 
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A consequence of AKT-phosphorylation on the unique serine residue is the 
association of KHSRP with the multifunctional protein 14-3-3 (Gherzi et al., 2010). This 
association prevents the interaction of KHSRP with the exoribonucleolytic complex RNA 
exosome and impairs its ability to promote rapid mRNA decay (Gherzi et al., 2010). 
Instead, the KHSRP phosphorylation operated by MAPK14 compromises KHSRP 
binding to ARE-containing transcripts and KHSRP fails to promote their rapid decay, 
although the ability to interact with the mRNA degradation machinery is retained (Briata 
et al., 2005). Further, direct binding and phosphorylation of ATM on serine residues 
enhance KHSRP interaction with primary miRNAs and its miRNA-processing activity 
(Zhang et al., 2011).  
 
2. KHSRP FUNCTIONS 
The molecular functions of KHSRP in mRNA decay, alternative splicing, and 
miRNA biogenesis have been extensively investigated.  
2.1 Implication of KHSRP in mRNA decay 
In eukaryotes, productive expression of a gene involves multiple steps including 
gene transcription into mRNA in the nucleus, mRNA export into the cytoplasm upon 5' 
capping and polyadenylation, mRNA translation and, finally, mRNA degradation in 
specific cytoplasmic location (Das et al., 2017; Bicknell & Ricci, 2017).  Degradation of 
mRNAs is a highly regulated process and mRNA stability, whose variability from one 
mRNA species to another is well known, plays a central role to define levels of gene 
expression (Houseley & Tollervey, 2009). Modulation of mRNA stability has been largely 
investigated and important advances in the characterization of the cis-acting RNA 
elements and the trans-acting cellular proteins that control mRNA decay have been made 
(Schoenberg & Maquat, 2012).  
AREs are landmark of cis-acting motifs responsible for rapid mRNA decay in 
mammalian cells and they can be found in the 3’ Untranslated Regions (3’ UTRs) of many 
short-lived transcripts encoding cytokines, cell-cycle regulators, cell type-specific 
transcription factors, and proto-oncogenes (Briata et al., 2012). AREs can differ in both 
length and AU content, and it does not exist a real consensus motif (Chen et al.,1994). 
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However, an intensive genome-wide bioinformatics approach was used to classify ARE-
containing transcripts into 5 clusters based on the number of overlapping AUUUA 
pentamers (Vlasova-St. Louis & Bohjanen, 2017). Numerous proteins have been 
described to bind to AREs, and called ARE-binding proteins (ARE-BPs) (Vlasova-St. 
Louis & Bohjanen, 2017). ARE-PBs compete with each other for ARE-binding and they 
have different functions: some of them, such as TTP and KHSRP, mediate transcript 
degradation, while others, such as ELAV-like protein 1 (ELAVL1; also known as HuR), 
mediate transcript stabilization, possibly by preventing binding by ARE-BPs that promote 
decay (Vlasova-St. Louis & Bohjanen, 2017). In addition, in the case of some ARE-BPs 
such as the heterogeneous nuclear Ribonucleoprotein D (hnRND; also known as AUF1), 
the mRNA destabilizing or stabilizing function is dependent on the cellular context 
and/or the expressed protein isoforms (Garneau et al., 2007). 
Most eukaryotic mRNA decay events are initiated by deadenylation and/or 
decapping, followed by 5’-exonucleolytic degradation operated by Xrn1 (Bicknell & Ricci, 
2017). Several eukaryotic deadenylases (including PAN2-PAN3, CCR4-NOT, and 
PARN) as well as decapping enzyme such as Dpc1/2 have been described (Das et al., 
2017; Zhang et al., 2015). Less commonly, endonucleases can initiate decay by internal 
cleavage thus leading to exonucleolytic decay in both directions from the cleavage site 
(Bicknell & Ricci, 2017). 3’- 5’ mRNA decay is also possible since unprotected 3’ end can 
be degraded by a large complex of 3’-to-5’ exonucleases known as the RNA exosome 
(Das et al., 2017) (Figure 7). The RNA exosome is a multi-protein complex formed by 10 
(Exo10Dis3) or 12 (Exo12Dis3/Rrp6/C1D) distinct subunits: the EXO9 core, which comprises 
the ‘cap’ structure (formed by Rrp4, Rrp40 and Csl4) and the ‘ring’ complex (formed by 
RNase PH-like proteins and Mtr3), is catalytically inactive and associates with the 
processive 3ʹ-to-5ʹ ribonuclease chromosome disjunction 3 (Dis3; also known as Rrp44) 
in cytoplasm and with the distributive 3ʹ-to-5ʹ exonuclease Rrp6 and its obligate binding 
partner C1D in the nucleus (Kilchert et al., 2016; Zinder & Lima, 2017).  
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Figure 7; Translation initiation and mRNA degradation (Bicknell & Ricci, 2017). 
 
During the years, many laboratories have been studying the role of KHSRP in 
the rapid decay of inherently labile transcripts as well as its ability to bind to AREs and to 
recruit the enzymatic complexes required for mRNA degradation (Chen et al., 2001; 
Gherzi et al., 2004; Chou et al., 2006; Gherzi et al., 2010; Briata et al., 2013). KHSRP 
binds to ARE-containing mRNAs and forms a complex with mRNA decay enzymes 
including the poly(A)-RNase (PARN), the RNA exosome component Rrp4, and the 
decapping enzyme Dcp1/Dcp2 (Chen et al., 2001; Gherzi et al., 2004; Chou et al., 2006). 
A global study has identified one hundred mRNAs that are physically associated with 
KHSRP and it was not surprising that many cytokines that contains AREs were identified 
as KHSRP targets and up-regulated upon its down-regulation, such as IL-8, IFN-α and 
IFN-β (Winzen et al., 2007; Lin et al., 2011; Gherzi et al., 2014). In addition, KHSRP 
promotes the decay of a number of regulators of cell identity and fate, such as Myogenin 
(Myog), Cyclin-dependent kinase 1 (Cdk1) and Utrophin (UTRN) in myogenesis, Nitric 
Oxide Synthase 2 (NOS2) and Tumor Necrosis Factor (TNF) in inflammatory response, 
Growth Associated Protein 43 (GAP43) in axonal outgrowth, Period Circadian Clock 2 
(Per2) in non-alcoholic liver steatosis (Briata et al., 2016). 
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2.2 Implication of KHSRP in pre-mRNA alternative splicing  
Alternative splicing (AS) is an important and versatile mechanism of gene 
expression control through which a pre-mRNA is processed into multiple mRNA 
isoforms differing in their combination of exon sequences thus allowing functional and 
genetic variability (Black & Grabowski, 2003). It is estimated that 95% of human genes 
are alternatively spliced (Pan et al., 2008). Although the regulation of splice site usage is 
still unclear, it is well known that numerous RBPs are involved in the control of AS (Black 
& Grabowski, 2003). The interaction of cis-sequence elements and trans-acting RBPs 
modulate the splicing process that can be highly variable as these interactions are transient 
and of relatively low specificity. Importantly, both changes in cis-sequence and levels 
of trans-factors can alter mRNA splicing and cause disease (Fredericks et al., 2015). A 
major group of splicing factors is represented by the heterogeneous nuclear 
ribonucleoprotein particles (hnRNPs) (Chaudhury et al., 2010). Among them, hnRNPA1 
whose association with KHSRP in different cell type has been demonstrated (Ruggiero et 
al., 2007; Michlewski & Càceres, 2010).  
KHSRP has been initially described as an essential component of a multiprotein 
complex that binds specifically to a G+U-rich intronic splicing enhancer element 
downstream of the neuron-specific c-src N1 exon (Min et al., 1997). In detail, KHSRP 
induces the assembly of five other proteins, including hnRNPF, hnRNPH and PTB, to 
the splicing enhancer (Min et al., 1997). Min and colleagues suggested that KHSRP is 
involved in the splicing of other transcripts besides c-src (Min et al., 1997). Indeed, it was 
observed both in vivo and in vitro that KHSRP associates with hnRNPH1 and 
Nucleophosmin (NMP), and that complex interacts with intron 3 of human RPL3 gene 
thus promoting the expression of an alternative isoform of RPL37 (Russo et al., 2011). 
 
2.3 Implications of KHSRP in miRNA biogenesis 
MiRNAs are short non-coding RNAs (~21-nucleotide in length) that exert key 
roles in the post-transcriptional regulation of gene expression. It has been predicted that 
miRNAs control the expression of about 50% of all protein-coding genes in mammalian 
cells (Krol et al., 2010). Many studies revealed that miRNAs regulate nearly every aspect 
of cell life interacting with specific mRNA targets, inhibiting their translation and favoring 
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their decay (Krol et al., 2010). Importantly, a single miRNA can modulate the expression 
of multiple target mRNAs to rapidly modify complex cellular functions, while one gene 
may be targeted by more than one miRNA (Hashimoto et al., 2013).  
The transcription of the precursors of miRNAs is carried out by RNA 
polymerase II (RNA Pol II) and it is controlled by RNA Pol II-associated transcription 
factors as well as by epigenetic regulators (Ha & Kim, 2014). Primary mi-RNAs (pri-
miRNAs) typically consist of a double-stranded stem of 33–35 bp, a terminal loop, and 
single-stranded RNA segments at both the 5ʹ and 3ʹ sides undergo several steps of 
maturation (Ha & Kim, 2014). A complex that includes the nuclear RNase III Drosha co-
transcriptionally initiates pri-miRNA maturation process by cropping the stem–loop to 
release a small hairpin-shaped RNA of ~65 nucleotides called precursor mi-RNA (pre-
miRNA) (Ha & Kim, 2014). The dsRNA-binding domain of Drosha is necessary but not 
sufficient for substrate interaction, thus additional RNA-binding activity is provided by 
DGCR8 recruited through the middle region of Drosha (Ha & Kim, 2014). Drosha 
cleaves the hairpin at approximately 11 bp away from the ‘basal’ junction between single-
stranded RNA and dsRNA, and approximately 22 bp away from the ‘apical’ junction 
linked to the terminal loop (Ha & Kim, 2014). Next, pre-miRNA is exported into the 
cytoplasm where it is cleaved near the terminal loop by a second ribonuclease Dicer-
containing complex generating a small RNA duplex (the two RNA-filament have been 
historically called ‘guide’ and ‘passenger’, respectively) (Ha & Kim, 2014). Subsequently, 
the RNA duplex is loaded onto an AGO protein (four distinct AGO proteins exist in 
humans) to form an effector complex called RNA-Induced Silencing Complex (RISC) 
that quickly removes one of the two strands holding the other filament to generate a 
mature RISC (Ha & Kim, 2014; Nakanishi, 2016) (Figure 8). MiRNAs are highly stable 
once they enter the RISC because both ends are protected by AGO proteins (Ha & Kim, 
2014). RISC recognizes its target mRNA based on the miRNA-target sequence 
complementarity and the accessibility of the target site (Jo et al., 2015). Once bound the 
target, the RISC complex inhibits protein synthesis by either repressing translation or 
promoting mRNA deadenylation and decay (Bartel, 2009; Jo et al., 2015).  
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Figure 8; MicroRNA biogenesis (Winter et al., 2009). 
 
Changes in the expression of miRNAs are associated with a number of human 
pathologies and, over the last decade, it has become clear that miRNAs are widely 
dysregulated in cancer (Krol et al., 2010; Calin & Croce, 2006; Visone & Croce, 2009). 
MiR-200 family members (miR-200s), often highly expressed in epithelial cells compared 
to mesenchymal cells, are downregulated during EMT (Bullock et al., 2012; Ding, 2014). 
MiR-200 family is composed of five different members (miR-200a, miR-200b, miR-200c, 
miR-141 and miR-429) that have been classified into two functional groups based on the 
seed sequence (Senfter et al., 2016). It has been shown that the miR-200 family is able to 
target and downregulate ZEB1 and ZEB2 thus promoting Cdh1 expression and the 
epithelial phenotype (Senfter et al., 2016). Conversely, the expression of miR-21 (a TGF-
β-induced miRNA in solid cancers) and miR-155 (that, among others, targets RhoA 
GTPase, a key regulator of cell polarity and tight junction formation) is increased during 
EMT (Volinia et al., 2006; Kong et al., 2014). 
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In the laboratory where I conducted my thesis, it has been discovered that 
KHSRP binds to the TL of a cohort of pre-miRNAs and interacts with both Drosha and 
Dicer complexes to promote pre-miRNAs maturation (Trabucchi et al., 2009).  
Further studies have confirmed the role of KHSRP in miRNA biogenesis in 
different cell lines (Liu & Liu, 2011; Michlewski & Càceres, 2010; Castilla-Llorente et al., 
2013) (Figure 9).  MiRNAs whose biogenesis is favored by KHSRP exert important 
functions in various biological processes as cell proliferation, immune response, metabolic 
homeostasis, and cell fate determination in response to extracellular stimuli (Gherzi et al., 
2010; Briata et al., 2016). 
 
 
Figure 9; Recognition of the pre-miRNA TL by KHSRP (image modified from Castilla-Llorente et al., 2013). 
 
KHSRP can interact and/or compete with other proteins to regulate the 
biogenesis of specific miRNAs in different contexts and cell types (Rüegger & Großhans, 
2012; Repetto et al., 2012). Lin-28 homolog A (LIN28) protein is able to repress the 
maturation of let-7 family members by interacting with the TL of let-7 precursors and by 
interfering with the Drosha and Dicer cleavage (Viswanathan & Daley, 2010). Moreover, 
LIN28 promotes 3’-uridylation of pre-let-7 that inhibits Dicer cleavage leading to 
degradation of the pre-let-7 itself (Heo et al., 2008). In different cell contexts, LIN28 and 
hnRNPA1 compete with KHSRP for pri-let-7a processing (Trabucchi et al., 2009; 
Michlewski et al., 2010). Since KHSRP also controls the decay of hnRNPA1 mRNA 
(Ruggiero et al., 2007), it is possible to hypothesize that KHSRP functions in mRNA 
decay and in miRNAs maturation are connected (Ruggiero et al., 2007; Michlewski & 
Càceres, 2010).  
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2.4 Novel functions: KHSRP can interact with long non-coding 
RNAs 
Long non-coding RNAs (lncRNAs) are a numerous and loosely classified group 
of long transcripts with no apparent protein-coding potential (Quinn & Chang, 2016). By 
convention, lncRNAs are defined as non-coding transcripts longer than 200 nucleotides 
(Rinn and Chang, 2012). Even if the function of the majority of lncRNAs is still unknown, 
some lncRNAs (e.g. XIST, HOTAIR, TERC, etc.) have been extensively investigated and 
characterized (Quinn & Chang, 2016).  
LncRNAs are involved in important biological events and specific patterns of 
their expression coordinate cell state, differentiation, development, and disease (Ponting 
et al., 2009; Rinn & Chang, 2012; Batista & Chang, 2013; Flynn & Chang, 2014). 
Accordingly, deregulations of lncRNA expression or mutations of the relative genes have 
been implicated in numerous human diseases (Esteller, 2011). Aberrant expression of 
lncRNAs plays a considerable role also in tumorigenesis, with several hundred 
dysregulated lncRNAs which have been recorded in human cancers so far (Gibb et al., 
2011; Prensner & Chinnaiyan, 2011). Potentially, dysregulation of lncRNAs may 
contribute to each of the hallmarks of cancer cells: (I) sustained proliferative signaling, (II) 
evasion of growth suppressors, (III) replicative immortality, (IV) invasion and metastasis, 
(V) induction of angiogenesis, (VI) and resistance to cell death (Gutschner et al., 2012). 
An increasing number of lncRNAs have being implicated in the regulation of EMT 
through various molecular mechanisms that include their function as competing 
endogenous RNAs (ceRNAs) for miRNAs involved in EMT regulation, and the 
epigenetic silencing of gene expression via the recruitment of the polycomb repressor 
complex 2 (PRC2) (Heery et al., 2017).  
A further layer of complexity has been provided by recent evidences that a 
number of lncRNAs potentially include short open reading frames (ORF). Some 
annotated lncRNAs are found associated with ribosomes and they code for short 
functional peptides (Dinger et al., 2008; Ingolia et al., 2011). For example, in Drosophila 
the tarsal-less/polished rice transcript is currently known to code for very short functional 
peptides (Tupy et al., 2005; Kondo et al., 2010). However, the ability to recruit the 
ribosome and be translated would not preclude the non-coding function of these 
transcripts (Ulitsky & Bartel, 2013). 
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Considering its versatility and ability to interact with different RNA species, it is 
not surprising that KHSRP associates with lncRNAs. It has been recently reported that 
the oncogenic H19 lncRNA directly interacts with KHSRP in undifferentiated 
multipotent mesenchymal C2C12 cells thus favoring KHSRP-mediated destabilization of 
labile myogenin mRNA (Giovarelli et al., 2014). In the early steps of myogenesis, AKT1 
and AKT2 are activated and directly phosphorylate KHSRP inducing its dismissal from 
H19 with the consequent stabilization of myogenin mRNA (Giovarelli et al., 2014). 
Further, KHSRP translocates to the nucleus of differentiating C2C12 cells where it 
promotes myogenic-miRNAs maturation favoring myogenic differentiation (Giovarelli et 
al., 2014). It is likely that regulatory mechanisms involving lncRNAs and KHSRP might 
exist in other cell types. 
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RESVERATROL 
 
Currently, cancer is treated by diverse therapeutics tools, such as surgery, 
radiotherapy, chemotherapy, hormonal therapy, immunotherapy, and targeted therapies 
(Palumbo et al., 2013). However, the genetic heterogeneity of cancer evades these 
treatment pathways and continuously deters clinical efforts (Block et al., 2015). To 
overcome the limitations and provide more effective cancer treatment, the development 
of low-toxicity broad-spectrum therapies that can collectively impact important 
mechanism and pathways for the genesis and spread of cancer has been pursued (Block 
et al., 2015). Consequently, the interest in chemopreventive activities of phytochemicals 
on cancer have been continuously growing. 
 
Stilbenes are molecules that contribute to flavor and color of many fruits and 
plants, as well as to growth, development, and defense from pathogens and herbivores 
(Dewick, 2002; Chong et al., 2009). Structurally, stilbenes are formed by two phenolic 
rings connected by an ethene molecule (Rocha-González, 2008). Resveratrol (RESV; also 
known as 3,4’,5-trihydroxystilbene) is the main stilbene generated in the skin of grapes, 
raspberries, mulberries, pistachios and peanuts, and by at least 72 medicinal and edible 
plants species (Rocha-González, 2008). From a chemical point of view, RESV is a 
polyphenolic phytoalexin that exists in two isomers, cis-(Z) and trans-(E) RESV, both with 
biological activity, although trans-RESV seems to have a more potent activity than cis-
RESV (Orallo, 2006).  
RESV exerts a number of biological activities, as anti-inflammatory, anti-
proliferative, and anti-oxidant effects, and both basic and preclinical studies have assigned 
to the molecule health-promoting effects in cardiovascular and neurodegenerative 
diseases, in diabetes, and also in cancer (Weiskirchen & Weiskirchen, 2016; Baur & 
Sinclair, 2006; Latruffe et al., 2015; Han et al., 2015) (Figure 11). RESV affects different 
steps of carcinogenesis, such as tumor initiation, tumor promotion and progression, neo-
angiogenesis and metastasis formation (Ferraz da Costa et al., 2017). In addition, in 
various cancer types, RESV behaves as a chemo-sensitizer by lowering the threshold of 
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cell death induction by classical anticancer agents and counteracts tumor cell 
chemoresistance (Ferraz da Costa et al., 2017).  
 
 
Figure 11; Some of the reported beneficial effects of RESV on organ function (Weiskirchen & Weiskirchen, 
2016). 
 
Although there are still unsolved mechanistic questions to be faced, RESV holds 
promising anti-tumor potential through its ability to induce apoptosis as well as to 
suppress both proliferation and invasion in a number of cell lines (Han et al., 2015; Xu et 
al., 2015). It has been suggested that the anti-proliferative properties of RESV are related 
to its capacity to block DNA synthesis as well as to interfere with various stages of cell 
progression by regulating the machinery of proteins involved in cell cycle control (Ferraz 
da Costa et al., 2017). In some cases, the induction of cell cycle arrest by RESV is followed 
by apoptotic cell death with activation of pro-apoptotic molecules and inhibition of anti-
apoptotic molecules (Lin et al., 2011). Independent studies showed that RESV can also 
induce p53-dependent cell death in a variety of cancer cell lines (She et al., 2001; Hsieh et 
al., 2011; Ferraz da Costa et al., 2017). Furthermore, a functional wild-type p53 protein is 
required to increase the RESV-sensitivity of tumor cells (Ferraz da Costa et al., 2017) 
(Figure 12). 
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Figure 12; Effects of RESV on p53 pathway in cancer cells (Ferraz da Costa et al., 2017). 
 
The capacity of RESV to interact with numerous proteins and biomolecules 
could explain why it acts upon various different signaling and can modulate gene 
expression (Britton et al., 2015). RESV can directly bind to its targets, altering their 
activity, structure and/or stability (Britton et al., 2015). Some examples are reported 
below. 
1) It has been postulated that RESV produces a neuroprotective activity against 
Alzheimer’s Disease since it indirectly stimulates the proteosomal degradation of β-
amyloid peptides (Marambaud et al., 2005). Chen and colleagues have reported that the 
microglial Nuclear Factor-κB (NF-κB) signaling mediates β-amyloid peptides-dependent 
neurodegeneration and that this pathway is inhibited by RESV through Sirtuin-1 (SIRT1) 
modulation (Chen et al., 2005). Accordingly, RESV strikingly reduces the expression of 
genes modulated by NF-κB (Chen et al., 2005). Further, RESV allosterically binds to 
SIRT1 and lowers the Km of SIRT1 for acetylated substrate (Canto et al., 2012). As a 
consequence, RESV, activating SIRT1, regulates different downstream targets through 
deacetylation (Canto et al., 2012). A recent study has demonstrated a new role for RESV 
in limiting TGF-β2-induced EMT through SIRT1 activation that lead to SMAD4 
deacetylation, which in turn modulates the expression of target molecules, such as 
CDH1 and Actin (ACTA2) (Ishikawa et al., 2015).  
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2) Not all RESV effects are SIRT1-dependent. It has been reported that RESV 
can directly bind to both DNA and RNA, and it is also involved in alternative splicing 
regulation (Usha et al., 2005; Markus et al., 2011). RESV can promote exon inclusion in 
an RNA-specific manner and can influence the levels of a group of splicing factors, 
including ASF/SF2, hnRNPA1 and HuR (Markus et al., 2011).  
3) Target-fishing and drug responsive target stability experiments showed 
selective, direct binding of RESV to KHSRP pointing out a KHSRP role for the post-
transcriptional effect of RESV (Bollmann et al., 2014). RESV/KHSRP interaction 
prevents KHSRP phosphorylation by MAPK14 thus enhancing KHSRP ability to bind 
to its target mRNAs as well as KHSRP association with the RNA exosome (Bollmann et 
al., 2014) As a result, TNF, IL8 and NOS2 mRNA half-life decreased with the consequent 
reduction of their steady-state levels (Bollmann et al., 2014). This observation could 
explain, at least in part, the anti-inflammatory effect of RESV (Bollmann et al., 2014).  
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Aims of the Study 
 
 
Metastases are formed when cancer cells break away from where they first 
originated (primary tumor), travel through the blood or lymphatic system, and form new 
tumors (metastatic tumors) in other parts of the body (Tam & Weinberg, 2013). EMT active 
role during metastasis is suggested by several experimental and clinical lines of evidence 
(Trimboli et al., 2008; De Craene & Berx, 2013). The activation of EMT program depends 
on the convergence of multiple signals from the surrounding microenvironment with 
TGF-β being recognized as a major inducer (Xu et al., 2009). Although transcriptional 
regulation of factors involved in EMT has been established, post-transcriptional 
regulation has been addressed more recently (Lamouille et al., 2009; Aparicio et al., 2013).  
Since 1996, multiple roles of the single-strand RNA-binding protein KHSRP 
have been studied (see Briata et al., 2016 for a recent review). In the last decade, in the 
laboratory where I conduct my thesis, a role for KHSRP as a negative regulator of gene 
expression at a post-transcriptional level has been investigated (Trabucchi et al., 2009).  It 
has been demonstrated that KHSRP operates by promoting decay of unstable mRNAs 
and favoring maturation from precursors of select miRNAs (Trabucchi et al., 2009). More 
recently, it was shown that KHSRP is a component of the TGF-β/BMP signaling pathway 
in multipotent mesenchymal C2C12 cells (Pasero et al., 2012). Based on these previous 
data, the aims of this study were: 
1. to investigate KHSRP role in TGF-β-dependent EMT in mammary gland cells; 
2. to search for compounds able to interfere with KHSRP function.  
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Experimental Procedures 
 
 
Cell cultures and treatments 
Murine immortalized NMuMg cells (obtained from ATCC) were cultured in 
DMEM plus 10% FBS and 10 mg/ml bovine insulin (Sigma-Aldrich). HEK293 cells 
(obtained from ATCC) were cultured in DMEM plus 10% FBS. Py2T cells, a kind gift of 
Dr. G. Christofori (University of Basel), were cultured in DMEM plus 10% FBS as 
described (Waldmeier et al, 2012). The immortalized HMLE cells, a kind gift of Dr. R. 
Weinberg (Whitehead Institute), were cultured as described (Elenbaas et al, 2001). Human 
mammary gland adenocarcinoma cells MDA-MB-231 and MCF7 were cultured in 
DMEM plus 5% FBS; human non-tumorigenic epithelial cell line MCF 10A were cultured 
in DMEM/F12 plus 5% horse serum, 10 mg/ml bovine insulin (Sigma-Aldrich), EGF 
(20 ng/ml, Sigma-Aldrich), hydrocortisone (0.5 mg/ml, Sigma-Aldrich), and cholera toxin 
(100 ng/ml, Sigma-Aldrich). 4T1 and TS/A mouse mammary gland cancer cells (obtained 
from Dr. C. Bagni, VIB Center for the Biology of Disease) were cultured in DMEM/F12 
plus 10% FBS.  
NMuMg and Py2T cells were maintained in DMEM supplemented with 2% and 
1% FBS, respectively, for 8h–16h prior to the addition of 10 ng/ml human recombinant 
TGF-β1 purchased from R&D Systems. 
Resveratrol was purchased from Sigma (R5010), dissolved in DMSO at a 
100mM concentration, and used at a 75 μM concentration in the majority of the 
experiments. 
 
Cell transfections and adenoviral infections 
The adenoviral vectors pAdCMVnull (AdNull) and pAdKHSRP (full-length 
human KHSRP cDNA cloned into an Adenoviral-Type 5 backbone) were purchased 
from Vector Biolabs (Eagleville, PA, USA). HEK-293 cells were transfected using 
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Attractene transfection Reagent (Qiagen) while NMuMg, Py2T and 4T1 cells were 
transfected with Lipofectamine 2000 (ThermoFischer). Stable KHSRP knock-down was 
obtained using previously described silencing sequences cloned in pSuper-Neo 
(Oligoengine) for NMuMg and in pSuper-Puro (Oligoengine) for Py2T and 4T1. Stable 
NMuMg transfectants were obtained using G418 (Sigma) selection (800 μg/ml) while 
stable Py2T transfectants were obtained using Puromycin (ThermoFischer) selection (4.5 
μg/ml). Either stable hnRNPA1 knock-down (generated transfecting cells with 
hnRNPA1 shRNA plasmid [sc-35,576-SH, Santa Cruz Biotechnologies]) or stable 
KHSRP knock-down were obtained using Puromycin selection (5.0 μg/ml, 
ThermoFischer) in 4T1 cells. Double knock-down (shKHSRP/shhnRNPA1) was 
obtained transfecting cells with pSuper-Neo-shKHSRP and hnRNPA1 shRNA plasmid. 
Then transfected 4T1 cells were selected in both G418 (100 μg/ml) and Puromycin (5.0 
μg/ml). A minigene splicing reporter construct that contains the Cd44v8 exon and its 
flanking introns (kindly provided by Dr. Chonghui Cheng) was transfected into HEK-
293 cells using Attractene transfection Reagent (Qiagen). siRNAs utilized to knock-down 
human KHSRP (5′—GAUCAACCGGAGAGCAAGA—3′) and human hnRNPA1 (5′—
AACUUUGGUGGUGGUCGUGGA—3′) were purchased from Sigma. Mouse miR-
27b-3p mimic and anti-mmu.miR-27b-3p miScript miRNA inhibitor were from Qiagen. 
siRNAs utilized to knock-down murine hnRNPA1 were purchased from Santa Cruz (sc-
35576). miRCURY LNA mmu-miR-192-5p and mmu-miR-194-5p Inhibitors were from 
Exiqon. 
It is noteworthy that miR-27b-3p targets the 3’UTR region of Khsrp transcript 
that has not been included in our adenovirus-based vector and that the hairpin sequence 
cloned into the pSuper vector in order to stably silence KHSRP has been designed on the 
basis of the mouse sequence while the adenoviral vector overexpressing KHSRP includes 
the human cDNA that diverges from the mouse cDNA in the region targeted by the 
hairpin. 
 
Phalloidin staining 
Mock and shKHSRP NMuMg cells were fixed in 3.7% formaldehyde, stained 
using Alexa Fluor 568 Phalloidin, and imaged with the Imager M2 microscope (Zeiss). 
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Scratch wound closure assay 
For TGF-β studies, cells were cultured in six-well plates up to sub-confluence 
and maintained in 2% FBS-containing medium for 16h. After starvation, a wound was 
scratched into confluent monolayers, and cultures were either maintained in 2% FBS 
containing medium for 48h or treated with 10 ng/ml TGF-β in the same medium for 
different times.  For RESV studies, NMuMg and 4T1 cells were cultured in six-wells plates 
up to confluence. A wound was scratched into monolayers and cultures were treated for 
40h with either RESV or DMSO. 
Images were taken using Olympus CKX41 microscope at different time post-
wounding and analyzed using the ImageJ package (http://imagej.nih.gov/ij/index.html). 
Average distance of wound obtained from six microscopic fields was used for calculation 
of percent wound healed. Experiments were performed three times. 
 
Immunofluorescence  
Cells were grown on chamber-slides, fixed with 3% paraformaldehyde in PBS 
and permeabilized with 0.5% Triton X-100 for 5 minutes at room temperature. 
Subsequently, cells were blocked with 3% bovine serum albumin for 30 minutes and 
incubated with affinity-purified anti-KHSRP antibody for 1h at room temperature and 
then incubated with Dylight 488-labeled secondary antibody (Abcam) for 1h at room 
temperature. Cells were imaged with the Imager M2 microscope (Zeiss). 
 
Antibodies 
Affinity-purified rabbit polyclonal anti-KHSRP antibody and the corresponding 
pre-immune serum were previously described (Pasero et al, 2012); rabbit polyclonal anti-
HDAC1, mouse monoclonal anti-ACTB (also known as β-actin), mouse monoclonal anti-
hnRNPA1 (4B10), and mouse monoclonal anti-TUBA1 (also known as α-tubulin) 
antibodies were from Sigma; anti-CDH2 rabbit polyclonal antibody was from Abcam; 
anti-FN1 (IST9) monoclonal antibody, anti-CDH1 (S-17) goat polyclonal antibody, and 
anti-14-3-3ξ goat polyclonal antibody (L-15) were from Santa Cruz; monoclonal antibody 
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to ESRP1/ESRP2 was from Rockland; rabbit polyclonal antibody to ESRP2 was from 
Abcam. Immunoblots were quantitated using ImageJ 1.49r software. 
 
RNA preparation, RT-PCR, and quantitative RT-PCR 
Total RNA was isolated using either the miRNeasy mini kit (Qiagen) or QIAzol 
Lysis Reagent (Qiagen) and retro-transcribed (50–100 ng) using either miScript reverse 
transcription kit (Qiagen) or Transcriptor Reverse Transcriptase (Roche) according to 
manufacturers' instructions. PCR analysis was performed using the GO-Taq system 
(Promega) and PCR products were analyzed by agarose (2% in TAE) gel electrophoresis. 
Quantitative PCR was performed using either the miScript SYBR green PCR kit (Qiagen) 
or the Precision 2× QPCRMasterMix (Primer Design), and the Realplex IIMastercycler 
(Eppendorf). For some experiments the end-points of the qPCR reactions were analyzed 
by agarose gel (2% in TAE buffer) electrophoresis. The sequence-specific primers utilized 
for PCR reactions are listed in Table 1. 
 
TRANSCRIPT FORWARD REVERSE 
mmu.Adamtsl2 CCTGGATTTGACAGCTCCGT GACATCTCCCACTGTGGTCC 
mmu.CD44 ATCCTCGTCACGTCCAACAC TCTTCTTCAGGAGGGGCTGA 
mmu.CD44s CACCTTGGCCACCACTAAGA CCCATTTTCCATTGTGTCTGGG 
mmu.CD44v CAACCACCAGGATGGCTGAT GCATGTGGGGTCTCCTCTTC 
mmu.Cdh1 GTGAGGACGACTAGGGGACT CACACTCAGGGAAGGAGCTG 
mmu.Cdh2 CGAGAGGCCTATCCATGCTG CCCAATATCCCCAGGGTGTG 
mmu.Cdkn2b GCAGCTGGATCTGGTCCTTGAGC CCCCTGCAGCAGCAGCTTGT 
mmu.Chst1 CCACCAGGTAACTGCTGTGT CAGGCCTTCAGGTGGAGAAG 
mmu.Col12a1 TGGTTAACGAACTGGGTCGG GAAAAGCATCAGGCGGACAC 
mmu.Col6a2 GGGGGTGGTCAACTTCGCCG CGGATGCCCTCTTCACGGGC 
mmu.Enah5+6C GAATGTCCAATGCTGCTGCC GGAAGCAGAGGAGTCTCCCA 
mmu.Enah5+6L TGTCCAATGCTGCTCCATCT CGGCTGGCAACTGGAATACT 
mmu.Ext1 GGACAGACTTCCCGAGCATC CTGAGAATGGATCAGCGGCA 
mmu.Ext2-001 GGAGAGAGCAAACCTGCCAT TGTGCTCTGCTGTGGATCTG 
mmu.Ext2-012 AGGCATTTTGTCACAGTCCCA AGCCTGCTCATCATTTGCCT 
mmu.Fn1 GCAGGAAAGTCACCCAGACA CTGTGGGAGGGGTGTTTGAA 
mmu.Fstl1 ACGCTCCCACCTTCGCCTCT GTCACCAGCGAGAGCGCCAG 
mmu.Fstl1 CCTCAGACAGAAGCCACAGG TGAGCGTCCATCCTTGGAAC 
mmu.Gpc6 CACGAACGCTGTAGTCCTGT GTGCTATAGTCGGGGATGGC 
mmu.IIIbFgfr2 CACGTGGAAAAGAACGGCAG AGAGCCAGCACTTCTGCATT 
mmu.IIIcFgfr2 AATATACGTGCTTGGCGGGT CTCCTTCTCTCTCACAGGCG 
mmu.Isg20-001 AAAGGGAGGAGTAGGGCAGG CTCAAGGCTGGCCAGGTAAG 
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mmu.Isg20-002 GCTGCTGTTTGTCAACTCTCC CACTCACCCTTTGAGGCCC 
mmu.Itga9 GGGTGGAGCATTGTCTTGGA TGATCCCTGGAGGGAGACTG 
mmu.Khsrp CCTGATTTTGGCTTTGGGGG CCAGTTTCTTGCTGTCTGGC 
mmu.Khsrp CCTGATTTTGGCTTTGGGGG CCAGTTTCTTGCTGTCTGGC 
mmu.Lrrd1-e1 ACAGCTTTGCCCAGTGGTAT TTCCATTGGCGGTCTCATCA 
mmu.Lrrd1-e2 GCTAAGCCCAGGCTAGGTTC ACACCTCTACAGTTGTTGCGA 
mmu.Mbp7-e7 GTGGTATGTGAGCACAGGCT GGATAGCTGGCCTGGAAGTG 
mmu.Mbp-e1-2 CATAGTATCCGCGCCCCAG CGACCCAATGGGGTGTTCAA 
mmu.miR-192-5p CTGACCTATGAATTGACAGCC  
mmu.miR-194-5p TGTAACAGCAACTCCATGTGGA  
mmu.miR-27b-3p TTCACAGTGGCTAAGTTCTGC  
mmu.Mmp9 AGGCTCTCTACTGGGCGTTA AGGAGTCTGGGGTCTGGTTT 
mmu.Plod2 GTTCCTCCAGGGCAAGTCTC ACTTGGAGCTGACGCTTGAA 
mmu.pri-194-1 CACCAGGCTCCAGGTTCAAT GTTTGCCGGATGGGTCCTTA 
mmu.pri-194-1 ATTTCTGGGTGGGCTCTTGG TCCTCTGCTGACCTAGCACT 
mmu.pri-miR-192 CGGCTAGTACCAGCAGAGGAAG ATGCCTGAAGACTGCTGTGTAGG 
mmu.pri-miR-194-1 CACCAGGCTCCAGGTTCAAT GTTTGCCGGATGGGTCCTTA 
mmu.pri-miR-194-2 GACTTCGCTCAGGGAGGTTG CGGCTCCAAGTCCACACTTT 
mmu.Rarres1 GCATGCGCACTTTCCTGATT GACGAAACCTTTTCCCAAAGCA 
mmu.Rpl32 CTGGCCATCAGAGTCACCAA TGCACACAAGCCATCTACTCA 
mmu.Runx2 GTACCCGGGGGAGACCGGTC TGCTGTGGCTTCCGTCAGCG 
mmu.Snai1 CAGGACTCCTTCCAGCCTTG CGGGTACAAAGGCACTCCAT 
mmu.sno234 TTCGTCACTACCACTGAGA  
mmu.Zeb1 AGCCTTAAGGAAGCAGCCAG ACATCAACACTGGTCGTCCC 
mmu.Zeb2 GTCTCTGCAAGTGCCATCCT ACTGACACGGGTGCTTCAAA 
qPCRskipv8 GAGGGATCCGGTTCCTGCCCC CAGTTGTGCCACTTGTGGGT 
qPCRv8inc CAATGACAACGCTGGCACAA CCAGCGGATAGAATGGCGCCG 
Table 1; List of primers used in the present study. 
 
In order to analyze gene expression changes among the pool of nascent mRNAs, 
we adopted the Click-iT Nascent RNA Capture kit (ThermoFischer) and performed 
experiments according to manufacturer’s instructions. NMuMg cells were pulsed with 0.5 
mM 5-ethynyl Uridine for 1 hour. 
 
Exon-level quantification and splicing analysis 
To test differences in exon usage, we followed the procedure described for 
DEXSeq (v 1.14.2, R 3.2.2) (Anders et al, 2012) adapting linear model design to test for 
differential usage induced by TGF- in the presence or absence of KHSRP 
overexpression (cells infected with either AdKHSRP or AdNull, respectively). In brief, 
we first created a GFF file from the Ensembl GRCm38.74 GTF with the provided script 
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dexseq_prepare_annotation. Reads counts were then collected from the sorted_by_name 
BAM, with dexseq_count.py on the previously created GFF reference in ‘‘unstranded’’ 
‘‘paired’’ mode. Exons with log2 fold change greater than j1.2j (linear FC 2.3), showing 
an adjusted p value <0.01 (FDR <1%, Benjamin-Hochberg corrected) were selected for 
downstream analysis. 
Electrophoretic mobility shift assays 
Electrophoretic mobility shift assays (EMSA) were performed as detailed in 
Trabucchi et al. (2009). Production and purification of recombinant KHSRP and GST-
hnRNPA1 have been described previously in Briata et al., 2005 and in Ruggiero et al., 
2007 respectively. The labeled RNA was transcribed using Sp6 polymerase from a 
template generated by inserting into pCY vector (Chen et al., 2000) a PCR product 
(forward primer: ATGCTGCAGTCCAGTACCAGTAAGA ATAC; reverse primer: AT 
GTCTAGACTCATCAGAATGGAATTAAGG). RNAs corresponding to ARETNF 
and E3 have been previously described (Gherzi et al., 2004; Giovarelli et al., 2014). 
 
Ribonucleoprotein complexes immunoprecipitation assays 
Ribonucleoprotein complexes immunoprecipitation (RIP) assays were 
performed as previously described (Giovarelli et al., 2014) with minor modification. 
Briefly, total cell lysates were immunoprecipitated with Dynabeads (Invitrogen, Carlsbad, 
CA) coated with protein A/protein G and pre-coupled to specific antibodies at 4ºC 
overnight. Pellets were washed three times with a buffer containing 50mM Tris-HCl [pH 
8.0], 150mM NaCl, 0.5% Triton X-100, 1X Complete (Roche). Total RNA was prepared 
from immunocomplexes using either the miRNeasy mini kit (Qiagen) or QIAzol Lysis 
Reagent (Qiagen), retro-transcribed, and amplified by qPCR as described above. The 
primer sequences are detailed in Table 1 (see before). 
 
Deep sequencing of small RNAs 
Twelve small RNA libraries were generated from total RNA samples (biological 
triplicates for each experimental condition) using the Illumina TruseqTM Small RNA 
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Preparation kit according to Illumina’s TruSeqTM Small RNA Sample Preparation Guide 
at LC Sciences (Houston, TX). The purified cDNA libraries were used for cluster 
generation on Illumina’s Cluster Station and then sequenced on Illumina GAIIx following 
vendor’s instructions. Raw sequencing reads (40 nts) were obtained using Illumina’s 
Sequencing Control Studio software version 2.8 (SCS v2.8) following real-time 
sequencing image analysis and base-calling by Illumina's Real-Time Analysis version 
1.8.70 (RTA v1.8.70). The extracted sequencing reads were further analyzed. First, the 
“impurity” sequences due to sample preparation, sequencing chemistry and processes, 
and to the optical digital resolution limits of the sequencer detector were removed. Those 
remaining sequ seqs (filtered sequ seqs with lengths between 15 and 32 bases) were grouped 
by families (unique seqs) and were used to map with the reference database files. The filtered 
unique seqs were aligned against mirs of mammals in miRbase. The mapped unique seqs were 
grouped as “unique seqs mapped to selected mirs in miRbase”, while the remaining ones 
were grouped as “unique seqs un-mapped to selected miRs in miRbase”. Bioinformatic data 
analysis was performed at LC Sciences. Raw data are available on the SRA archive under 
the BioProject ID PRJNA312753 (http://www.ncbi.nlm.nih.gov/bioproject/312753). 
 
Other experimental procedures 
Bioinformatic analysis and statistical evaluation of RNA-seq data have been 
performed by Dr. Gabriele Bucci at the ‘Department of Functional Genomics of Cancer’ (San 
Raffaele Hospital, Milan). 
 
 RNA deep-sequencing 
High-quality RNA was extracted from NMuMg cells (biological triplicates for 
each experimental condition), and a total of twelve libraries were prepared using standard 
Illumina TrueSeq SBS PE 200 cycles protocol and sequenced on HiSeq2500. Image 
analysis and base calling were performed using the HiSeq Control Software and RTA 
component from Illumina. This approach yielded between 33 and 69 millions of reads 
that were further processed. Raw data have been published on the SRA archive under the 
BioProject Accession PRJNA312702 (http://www.ncbi.nlm.nih.gov/bioproject/ 
312702). 
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 RNA-seq preprocessing and alignment 
Illumina 100bp Paired-End FASTQ files were quality checked with FASTQC 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc). Low quality bases and 
adapters sequences were trimmed with FASTX (http://hannonlab.cshl.edu/ 
fastx_toolkit). Preprocessed reads were aligned to mouse mm10/GRCm38 reference 
genome using STAR version 2.3.0 (Dobin et al., 2013) in paired end, unstranded mode. 
After alignment, putative PCR and optical duplicates were flagged with Picard 
MarkDuplicates version 1.128 (http://broadinstitute.github.io/picard). 
 
 RNA-seq analysis and differential expression gene analysis 
To quantify expression levels mapped reads were counted from BAM files with 
HTSeq-counts version 1.2.1 (Anders et al., 2015), in “intersection-strict” mode, feature 
type “exon” and id attribute “gene_name” against reference annotation Ensembl 
GRCm38.74. We tested for differential gene expression, at transcript level, with a custom 
R script following the DESeq2 (Anders, 2010) Bioconductor package. We considered as 
significantly regulated, those transcripts with a Benjamini-Hochberg adjusted p value < 
0.01 and an absolute log2 fold change > 1.2. 
 
 Gene ontology and pathway enrichment 
Gene lists were tested for enrichment in GO categories, protein-protein 
interactions networks and known pathways using EnrichR (Chen et al., 2013) and 
Cluego+Clupedia (Bindea et al., 2009) Cytoscape (Shannon et al., 2003) plugin. 
Enrichment were selected when p-value < 0.01 (EnrichR, Fisher exact test) or p-value < 
0.05 (ClueGO, two sided hypergeometric test, Bonferroni corrected). 
 
 RIP-seq peak detection and annotation 
Raw FASTQ reads were trimmed at the ends to remove low quality calls with 
FASTX (http://hannonlab.cshl.edu/fastx_toolkit). Paired reads were aligned to indexed 
mm10 genome with bowtie2 (Langmead et al., 2012) allowing for gapped pair-end 
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alignments. After-alignment statistics and metrics were collected and analyzed using 
samtools (Li et al., 2009) and Picard (https://github.com/broadinstitute/picard) suites. 
Peak calling on TGF-β treated and untreated RIP was done using MACS2 in absolute 
mode with the ‘no lambda’ ‘no model’ options set true. To keep only high scoring peaks 
the p-value filter was fixed to 0.01. We further discarded pileup regions with less than 3 
reads at summit. The resulting putative binding regions were annotated with mouse 
genome annotation Ensembl GRCm38.74. Bedtools (Quinlan et al., 2010) and custom 
scripts were used to differentially intersect peaks/genes position from the two dataset. 
 
Statistical methods 
Quantitative RT-qPCR: averaged CTs among replicates were tested for mean 
difference between conditions with Student’s T-test, and considered significant when 
nominal p < 0.01. 
Differential Expression Analysis: sample triplicates were processed and analyzed 
as described in the DESeq2, bioconductor manual. Genes having less than 1 CPM (Count 
Per Million) reads were excluded from the analysis. DESeq2 implements a method for 
differential analysis of count data, using shrinkage estimation for dispersions and fold 
changes to improve stability and interpretability of estimates. P-values are estimated using 
Wald-Test corrected by Benjamini and Hochberg (BH) multiple test. Genes were defined 
as significantly regulated when the tested coefficient p-values were below 0.01 and the 
mean, log2, absolute fold change per gene was higher than 1.2. 
Differential Exon Usage Analysis: the estimation of the isoform expression 
levels was achieved using DEXseq. Sample were processed and analyzed as described in 
the DEXseq bioconductor manual. The method uses a generalized linear model (negative 
binomial GLM) to estimate an overall expression level for each exon, then infers 
differential expression among genes and between condition triplicates. We adapted the 
model to fit our design’s condition (transfection) and treatment (TGF-β): 
formulaFullModel = ~ sample + exon + condition:exon + treatment:exon 
formulaReducedModel = ~ sample + exon + condition:exon 
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DexSeq calculates the probability of each exon within a gene, to be differentially 
expressed between condition, taking in to account the biological variability and 
experimental conditions. Using these p-values, a rejection threshold is chosen according 
to a multiple testing correction method (BH) at p < 0.01. 
RIP-Seq Peak Detection: low quality bases at the end of reads were trimmed 
with a threshold of Q30 (phred 33). Quality is assigned by the Illumina sequencer software 
and is expressed as the -10*log10 of the probability that the corresponding base call is 
incorrect. Aligned reads were analyzed using MACS2 and peaks were filtered at nominal 
p < 0.01. MACS2 employs a Poisson distribution to accurately approximate a binomial 
distribution model and test dynamic Poisson parameters for each genomic region. 
Gene Ontology and Pathway Enrichment: Gene Ontology enrichment were 
obtained from EnrichR web-application and ClueGO using p-value threshold of nominal 
p <0.01 and corrected p<0.05 respectively. The EnrichR p-values used in the present 
works refer to the Fisher Exact Test statistics, which is a proportion test that assumes a 
binomial distribution and independence for probability of any gene belonging to any set. 
ClueGO enrichment probabilities are calculated as a Bonferroni-Corrected, two-sided 
hypergeometric test. 
Deep sequencing of small RNAs: a proprietary pipeline script, ACGT101-miR 
v4.2 (LC Sciences), was used for sequencing data analysis and preprocessing. Two-way 
ANOVA was used to test for differentially expressed miRNAs. A cut off threshold was 
set to nominal p < 0.01. 
 
Accession numbers 
The accession numbers for the small RNA-seq and RNA-seq data reported in 
this article are NCBI SRA: SRP074885 and NCBI SRA: SRP070690, respectively. 
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Results 
 
 
1. KHSRP is downregulated during TGF-β-induced Epithelial-to-
Mesenchymal Transition in mammary gland cells 
In order to investigate whether KHSRP is implicated in TGF-β-induced EMT, 
we adopted the murine immortalized mammary epithelial cell line NMuMg as a model. 
These cells acquire a mesenchymal spindle-like fibroblast phenotype and display the gene 
expression pattern typical of EMT in response to TGF-β (Avery-Cooper et al., 2014).  
We treated NMuMg cells with 10ng/ml of TGF-β for different intervals of time 
(0, 1h, 8h, 24h, 48h, and 96h respectively) and we observed: 
 a rapid increase of Snai1, Zeb1, and Zeb2 mRNA expression levels; 
 a late increase of Cdh2 and Fn1 mRNA expression levels;  
 a rapid decrease of Cdh1 mRNA expression levels; 
 expression changes of EMT-related miRNAs, such as the decrease of miR-200-b (a 
member of miR-200 family) expression levels, and the increase of miR-155 
expression levels (Figures 13, left panel). 
Consistently with changes in mRNA levels, reduced levels of CDH1 protein as well as 
increased levels of CDH2 and FN1 proteins were detected after 48 hours of TGF-β 
treatment, as shown in Figures 13 (right panel). 
We verified that the TGF-β treatment is able to change the morphology of 
NMuMg cells from epithelial to mesenchymal after 48h from the beginning of treatment 
(Figure 14). 
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Figure 13; Left panel. RT-qPCR analysis of the indicated mRNAs and miRNAs in NMuMg cells treated with TGF-β 
for the indicated times. The values of RT-qPCR experiments shown are averages ± SEM of three independent 
experiments performed in triplicate. 
Right panel. Immunoblot analysis of total cell extracts (20 µg) from NMuMg cells treated with TGF-β for the 
indicated times or untreated (time 0). The indicated antibodies were used.  
 
 
Figure 14; Phase contrast microscopy of NMuMg cells serum-starved and either untreated (top panel) or treated 
with 10ng/ml of TGF-β for 48h (bottom panel). Scale bars: 100 µm. 
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Importantly, RT-qPCR analysis and immunoblot analysis revealed that KHSRP 
expression (both mRNA and protein) was silenced in a time-dependent manner in 
response to TGF-β (Figure 15), while its levels were restored when TGF-β was removed 
from the culture medium of cells previously exposed for 7 days to TGF-β (Figure 16).  
 
 
Figure 15; Left panel. RT-qPCR analysis of Khsrp in NMuMg either untreated (-) or treated (+) with TGF-β for the 
indicated times. The values of RT-qPCR experiments shown are averages ± SEM of three independent experiments 
performed in triplicate. Statistical significance: **p < 0.001 (Student’s t-test).  
Right panel. Immunoblot analysis of total cell extracts from NMuMg cells serum-starved and either treated with 
TGF-β (+) for the indicated times or untreated (-). The indicated antibodies were used. 
 
 
Figure 16; Immunoblot analysis of total cell extracts from NMuMg cells untreated (lane 1), treated with TGF-β for 
7 days (lane 2), or treated with TGF-β for 7 days and then cultured in normal growth medium for 5 days (lane 3). 
The indicated antibodies were used. Representative gels are shown. 
 
RT-qPCR analysis of nascent transcripts showed that TGF-β produces a limited 
change in Khsrp transcription (Figure 17) thus prompting us to investigate a post-
transcriptional mechanism for TGF-β-dependent KHSRP silencing.  
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 Figure 17; RT-qPCR analysis of nascent Khsrp transcript Click-iT (see the ‘Experimental Procedures’) in NMuMg 
cells either untreated (-) or treated with TGF-β for 24h (+). The values of RT-qPCR experiments shown are averages 
± SEM of three independent experiments performed in triplicate. 
 
We focused on miRNAs as potential regulators of KHSRP expression in 
response to TGF-β. A genome-wide deep RNA sequencing (RNA-seq) analysis 
performed on the small RNA population (see below) revealed that two miRNAs, miR-
27b-3p and miR-181a, are induced by TGF-β in NMuMg cells with timing compatible 
with KHSRP downregulation (Figure 18).  
 
 
Figure 18; Left panel. RT-qPCR analysis of miR-27b-3p in NMuMg cells treated with TGF-β for the indicated times. 
Right panel. RT-qPCR analysis of miR-181a in serum-starved NMuMg cells TGF-β-treated for the indicated times.  
The values of RT-qPCR experiments shown are averages ± SEM of three independent experiments performed in 
triplicate. Statistical significance: *p < 0.01, **p < 0.001 (Student’s t-test). 
 
It was previously reported that both miR-27b-3p and miR-181a target KHSRP 
and modulate its expression (Zhou et al., 2012; Sundaram et al., 2013). Thus, we 
hypothesized that a similar regulatory pathway was operative also in NMuMg cells. In 
order to verify this hypothesis, we investigated if manipulations of the levels of miR-27b-
3p and miR-181a were able to affect KHSRP expression levels. We overexpressed the 
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two miRNAs in NMuMg cells through transient transfections of either miR-27b-3p 
mimic or miR-181a mimic (Figure 19). Interestingly, miR-27b-3p overexpression caused 
KHSRP downregulation in NMuMg cells, while miR-181a did not produce any effect 
(Figure 20). 
 
 
Figure 19; RT-qPCR analysis of miR-27b-3p and miR-181a in control (mimic-miR-C), mimic-miR-27b-3p, and mimic-
miR-181a transfected NMuMg cells. The values of RT-qPCR experiments shown are averages ± SEM of three 
independent experiments performed in triplicate. 
 
 
Figure 20; Left panel. Immunoblot analysis of total cell extracts (20 μg) from either control- (mimic-miR-C) or 
mimic-miR-27b-3p- transfected NMuMg cells.  
Right panel. Immunoblot analysis of total cell extracts (20 μg) from either control- (mimic-miR-C) or mimic-miR-
181a-transfected NMuMg cells.  
The indicated antibodies were used. The position of molecular mass markers is indicated on the left of each 
immunoblot.  Representative gels are shown. 
 
Further, we transiently silenced miR-27b-3p expression and we demonstrated 
that miR-27b-3p silencing prevented TGF-β-induced KHSRP downregulation (Figure 21). 
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Altogether, these results indicate that KHSRP is silenced by miR-27b-3p in mammary 
gland cell lines that undergo EMT in response to TGF-β.  
 
 
Figure 21; RT-qPCR analysis of Khsrp mRNA in either control (anti-miR-C) or anti-miR-27b-3p transfected NMuMg 
cells either untreated (-) or treated (+) with TGF-β for 24h. The values of RT-qPCR experiments shown are averages 
± SEM of three independent experiments performed in triplicate. Statistical significance: **p < 0.001 (Student’s 
t-test). 
 
The observation that TGF-β causes KHSRP silencing was extended to other 
mammary epithelial cell lines known to undergo EMT in response to TGF-β treatment, 
such as human non-tumorigenic MCF 10A, human non-transformed mammary epithelial 
(HMLE) cells, and murine Py2T cells (Figure 22).  
 
 
Figure 22; Immunoblot analysis of total cell extracts (20 µg) from HMLE, MCF 10 A, and Py2T cells, serum-starved 
and either treated with TGF-β (+) for 5 days or untreated (-). The position of molecular mass markers is indicated 
on the left of each immunoblot. Representative gels are shown. 
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Conversely, TGF-β did not reduce KHSRP expression in breast cancer cell lines 
that display a limited EMT response to TGF-β such as MDA-MB-231, 4T1, TS/A, 
HMLER, and MCF7 (Figure 23 and data not shown). MDA-MB-231, MCF7 and HMLER 
are human mammary cells, while 4T1 and TS/A are murine mammary cells. All these cell 
lines are models of advanced stage of tumor transformation, and some of them have 
strong invasive properties. 
 
 
Figure 23; Immunoblot analysis of total cell extracts (20 μg) from MDA-MB-231, 4T1, and TS/A cells, serum-
starved and either treated with TGF-β (+) for 3 days or untreated (-). The position of molecular mass markers is 
indicated on the left of each immunoblot. Representative gels are shown. 
 
 
2. Forced KHSRP expression prevents TGF-β-induced EMT 
and reprograms the transcriptome of NMuMg cells 
We decided to investigate whether KHSRP downregulation is required for TGF-
β-induced EMT and, to this purpose, we manipulated KHSRP expression levels. We 
transiently overexpressed KHSRP cloned in an adenoviral vector (AdKHSRP) in order 
to maintain constant its levels during TGF-β treatment in NMuMg cells (Figure 24), and 
analyzed the expression of some factors known as hallmarks of EMT induction. As shown 
in Figure 25, KHSRP overexpression significantly impaired the TGF-β-dependent 
induction of Snai1, Fn1 and Cdh2 mRNAs as well as the expression of CDH2 protein 
when compared to control-infected (AdNull) cells.  
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Figure 24; Immunoblot analysis of total cell extracts (20 µg) from NMuMg cells infected with either control (Ad-
Null) or KHSRP-expressing (AdKHSRP) adenoviral vectors for 24h and subsequently serum-starved and either 
treated with TGF-β (+) for 24h or untreated (-). The indicated antibodies were used. The position of molecular 
mass markers is indicated on the left. Representative gels are shown. 
 
 
 
Figure 25; Left panel. RT-qPCR analysis of the indicated transcripts in NMuMg cells infected with either control 
(AdNull) or KHSRP-expressing (AdKHSRP) adenoviral vectors for 24h and subsequently serum-starved and either 
treated with TGF-β (+) for 24h or untreated (-). 
Right panel. Immunoblot analysis of total cell extracts from cells treated as in left panel. The indicated antibodies 
were used. The position of molecular mass markers is indicated on the left. Representative gels are shown. 
 
In order to investigate the changes induced in the whole transcriptome by 
sustained KHSRP expression, we performed RNA-seq analyses. The results of the 
bioinformatic analyses of RNA-seq data are accessible at NCBI SRA: SRP074885 and 
NCBI SRA: SRP070690. Gene Ontology (GO) enrichment analysis of RNA-seq data 
revealed that KHSRP-regulated transcripts were mainly involved in cell adhesion, cell 
motility/migration, and cytokine/receptor interaction (Figure 26).  
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Figure 26; Gene Ontology (GO) analysis. RNA isolated from either AdNull- or AdKHSRP- expressing and TGF-β-
treated NMuMg cells was subjected to RNA-seq analysis. Genes showing a log2-fold change >1.5 in the biological 
triplicates were used for GO analysis, and the enrichment of the KHSRP-regulated pathways are presented as pie 
graph. 
 
The RT-qPCR-based validation of some of the RNA-seq data showed that 
KHSRP overexpression counteracts the TGF-β-dependent induction of transcripts 
relevant to collagen metabolism (e.g. Col12a1 and Col6a2), cell adhesion (e.g. Iglon5), TGF-
β signaling (e.g. Fstl1), extracellular matrix organization (e.g. Adamtsl2, Gpc6 and Wisp2), 
cytokine-receptor interaction (e.g. Ccl17), and glycosaminoglycan metabolism (e.g. Chst1) 
(Figure 27). A detailed list of the expression levels of these transcripts in NMuMg in 
different contexts is presented in Table 2 at the end of the ‘Results’ section.  
 
 
Figure 27; RT-qPCR analysis of the indicated transcripts in cells treated in NMuMg cells infected with either control 
(AdNull) or KHSRP-expressing (AdKHSRP) adenoviral vectors for 24h and subsequently serum-starved and either 
treated with TGF-β (+) for 24h or untreated (-). 
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Next, we verified if, as a consequence of KHSRP-induced changes in the 
expression of genes involved in cell adhesion and motility, KHSRP overexpression 
affected the migratory proprieties of NMuMg cells in comparison to control cells. We 
performed scratch wound assays in both cell lines and, in agreement with transcriptomic 
changes, we found that KHSRP overexpression in TGF-β-treated cells reduces the size 
of the wound closure when compared to negative control cells (Figure 28).  
 
 
Figure 28; Scratch wound healing assay. NMuMg cells were cultured as described in ‘Experimental Procedures’ 
section and scratch wounds were introduced into confluent monolayers. Cultures were photographed and the 
width of the wound was measured at 0h and 48h after the scratch was made. The percentage of the wound healed 
area for each culture condition was plotted (top right bar graph). Representative images are shown. Scale bars 
represent 100 mm. 
 
Finally, miR-27b-3p downregulation, similar to KHSRP overexpression, 
prevented TGF-β-dependent induction of Snai1, Fn1, Cdh2, Zeb1, and Zeb2 gene 
expression (Figure 29 and Table 2). 
Together, our results indicate that sustained KHSRP expression impairs the 
TGF-β-dependent induction of factors related to cell adhesion and motility and suggest 
that TGF-β-induced KHSRP silencing is required to enable NMuMg cells to acquire 
migratory properties. 
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Figure 29; RT-qPCR analysis of the indicated transcripts in NMuMg cells transfected with either control anti-
miRNA (anti-miR-C) or anti-miR-27b-3p and subsequently serum-starved and either treated with TGF-β (+) for 36h 
or untreated (-). The values of RT-qPCR experiments shown are averages (±SEM) of three independent 
experiments performed in triplicate. Statistical significance: *p < 0.005, **p < 0.001 (Student’s t-test). 
 
3. KHSRP knockdown mimics the phenotype of TGF-β-
induced EMT 
In order to unambiguously establish the role of KHSRP silencing as a key step 
in TGF-β-induced EMT, we stably knocked-down KHSRP (shKHSRP) in NMuMg cells 
(Figure 30). 
 
 
Figure 30; Immunoblot analysis of total cell extracts (20 µg) from either mock or shKHSRP NMuMg cells. The 
indicated antibodies were used. The position of molecular mass markers is indicated on the left of each 
immunoblot. Representative images are shown. 
 
Analyzing the gene expression pattern of these cells, we found that shKHSRP 
mimics the effect of TGF-β increasing the expression of EMT-related factors, such as 
Snail1, Fn1, Col6a2, Col12a1, Iglon5, Fstl1, Cd44, and Itga9 (Figure 31 and Table 2). 
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Figure 31; RT-qPCR analysis of the indicated transcripts in either mock or shKHSRP NMuMg cells that were serum-
starved and then either treated with TGF-β for 24h (+) or untreated (-). The values of RT-qPCR experiments shown 
are averages ± SEM of three independent experiments performed in triplicate. Statistical significance: **p < 0.001 
(Student’s t-test).  
 
In agreement with a role of miR-27b-3p in TGF-β-dependent KHRSP down-
regulation, we found that the forced miR-27b-3p expression induces the expression of 
some of critical EMT factors similar to KHSRP knockdown (Figure 32 and Table 2). 
 
 
Figure 32; RT-qPCR analysis of the indicated transcripts in either control miRNA mimic (mimic-miR-C) or mimic-
miR-27b-3p-transfected NMuMg cells. The values of RT-qPCR experiments shown are averages ± SEM of three 
independent experiments performed in triplicate. Statistical significance: *p < 0.01, **p < 0.001 (Student’s t-test). 
 
We also found that KHRSP silencing in NMuMg cells leads to changes on cell 
motility and morphology. Scratch wound assays showed that KHSRP knockdown 
accelerates the wound closure in both control and TGF-β-treated cells (Figure 33). 
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Moreover, transwell migration assays confirmed the evidence that KHSRP silencing 
enhances the migratory potential of NMuMg cells (Figure 34).  
 
 
Figure 33; Scratch wound healing assay. Either mock or shKHSRP NMuMg cells were serum-starved and then 
either treated with TGF-β or untreated. Scratch wounds were introduced into confluent monolayers. Cultures 
were photographed and the width of the wound was measured at 48h after the scratch was made (left panel). 
The percentage of the wound healed area for each culture condition was plotted in a bar graph (right panel).  
Representative images are shown. Scale bars represent 100 mm. 
 
 
Figure 34; Either mock or shKHSRP NMuMg cells were seeded in the upper chamber of a 24-well transwell 
migration insert and migration was quantitated by DAPI staining after 48h using a fluorescent microscope. Images 
were analyzed using ImageJ software.  
 
In agreement with the evidence that miR-27b-3p targets KHSRP (Yao et al., 
2016) and induces gene expression changes similar to the effect of KHSRP silencing, we 
found that the transient miR-27b-3p overexpression in NMuMg cells caused the 
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appearance of increased migration areas in scratch wound assays similar to KHSRP 
knockdown (Figure 35).  
 
Figure 35; Scratch wound healing assay. NMuMg cells were transiently transfected with either control (mimic-
miR-C) or mimic-miR-27b-3p and scratch wounds were introduced into confluent monolayers. Arrows point to 
cell migrating into the wound. Representative images are shown. Scale bars: 100 µm. 
 
Furthermore, KHSRP downregulation mimicked the TGF-β-mediated 
remodeling of the cytoskeleton from cortical actin to stress fibers as detected by phalloidin 
staining (Figure 36). 
 
 
Figure 36; Either mock or shKHSRP NMuMg cells were serum-starved and then either treated with TGF-β or 
untreated for 48h. Cells were stained using Alexa Fluor 568 Phalloidin to visualize the actin cytoskeleton. 
Representative images are shown. Scale bars represent 50 mm. 
 
58 
 
In order to extend our observations to another non-transformed mammary 
gland cell line, we stably knocked-down KHSRP in Py2T cells (Figure 37). Stable KHSRP 
knockdown mimicked the changes induced by TGF-β also in this cellular context (Figure 
38 and data not shown). Consistently, similar to NMuMg cells, KHSRP overexpression 
impaired the wound healing in Py2T cells, while its downregulation enhanced the gap 
closure (Figure 39 and data not shown). 
 
 
Figure 37; Immunoblot analysis of total cell extracts (20 µg) from either mock or shKHSRP Py2T. The indicated 
antibodies were used. 
 
 
Figure 38; RT-qPCR analysis of the indicated transcripts in either mock or shKHSRP Py2T cells. The values of RT-
qPCR experiments shown are averages ± SEM of three independent experiments performed in triplicate. 
Statistical significance: *p < 0.01, **p < 0.001 (Student’s t-test). 
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Figure 39; Scratch wound healing assay. Py2T cells were infected with either control (AdNull) or KHSRP-expressing 
(AdKHSRP) adenoviral vectors for 24 h and scratch wounds were introduced into confluent monolayers. Cultures 
were photographed 24 h and 48 h after scratch. Time 0 represents initial gap width at 0 h. The percentage of the 
wound healed area was plotted (right panel). Scale bars: 100 µm. 
 
Since EMT that can be reverted, at least in part (Prieto-Garcìa et al, 2017), we 
explored the possibility that forced KHSRP expression in NMuMg cells that express low 
KHSRP level (either due to KHSRP silencing or to TGF-β-dependent KHSRP 
downregulation) is able to revert the phenotypical changes related to EMT (Figure 40).  
 
  
Figure 40; Immunoblot analysis of total cell extracts (20 μg) from either mock or shKHSRP NMuMg cells infected 
with either control (Ad-Null) or KHSRP-expressing (AdKHSRP) adenoviral vectors for 24h and subsequently serum-
starved and either treated with TGF-β (+) for 24h or untreated (-). The indicated antibodies were used. 
 
We found that the transient KHSRP re-expression could revert the EMT-like 
phenotype of shKHSRP NMuMg cells to the epithelial phenotype (Figure 41).  
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Figure 41; RT-qPCR analysis of the indicated transcripts in either mock or shKHSRP NMuMg cells infected with 
either control (AdNull) or KHSRP-expressing (AdKHSRP) adenoviral vectors for 24h and subsequently serum-
starved and either treated with TGF-β (+) for 24h or untreated (-). The values of RT-qPCR experiments shown are 
averages (±SEM) of three independent experiments performed in triplicate. Statistical significance: *p < 0.01, **p 
< 0.001 (Student’s t-test). 
 
Most importantly, we showed that cells that achieved an established 
mesenchymal phenotype through a prolonged treatment with TGF-β reacquire an 
epithelial phenotype upon KHSRP re-expression and despite the continuous presence of 
TGF-β (Figure 42). 
 
 
Figure 42; Left panel.  Schematic of the NMuMg cell treatment. Right panel. RT-qPCR analysis of the indicated 
transcripts in cells treated as summarized in the left panel. The values of RT-qPCR experiments shown are 
averages ± SEM of three independent experiments performed in triplicate. Statistical significance: *p < 0.01, **p 
< 0.001 (Student’s t-test).  
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As a whole, these data indicate that KHSRP knockdown in untreated cells 
induces phenotypic changes that mimic TGF-β-induced EMT thus supporting our 
hypothesis that KHSRP silencing is a required event for EMT occurring in response to 
TGF-β. 
4. KHSRP-dependent maturation of miR-192-5p prevents 
the expression of some EMT factors 
KHSRP is a ubiquitous protein whose cellular localization varies in distinct cell 
types (Gherzi et al., 2014). Here, we found that KHSRP is almost exclusively located in 
the nucleus of mammary gland cells (Figure 43 and data not shown).  
 
 
Figure 43; Left panel. Immunoblot analysis of either nuclear (nuc) or cytoplasmic (cyto) extracts (20 µg) from 
NMuMg cells serum-starved and either treated with TGF-β (+) for the indicated time or untreated (-) for 18h. The 
indicated antibodies were used. The position of molecular mass markers is indicated on the left. Representative 
gels are shown. 
Right panel. Immunofluorescence microscopy analysis of KHSRP localization in NMuMg cells. Scale bars: 50 µm. 
 
In keeping with this finding, KHSRP does not affect the cytoplasmatic decay 
rates of inherent unstable mRNAs whose steady state levels are regulating by either its 
overexpression or down-regulation (data not shown).  
Either KHSRP silencing in cultured cell line and KHSRP gene knock-down in 
mice have demonstrated that KHSRP favors miRNA maturation from precursors 
(reviewed in Briata et al., 2016). To explore the role of KHSRP in TGF-β-controlled 
miRNA maturation on a transcriptomic scale, we performed an RNA-seq analyses of 
small RNAs in shKHSRP NMuMg cells as well as in mock-transfected cells as control. 
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Bioinformatic analysis of small RNA-seq data revealed that KHSRP knockdown 
significantly reduces the expression of a limited number of miRNAs (33 with p value < 
10-3 using ANOVA test). Our RT-qPCR-based validation revealed that KHSRP 
knockdown reduces the expression of miR-192-5p and miR-194-5p without affecting the 
levels of the corresponding primary transcripts (Figure 44 and data not shown) thus 
suggesting that KHSRP is required for the maturation of these miRNAs. Importantly, the 
levels of miR-192-5p and miR-194-5p were downregulated in the course of TGF-β-
induced EMT (Figure 45). 
 
 
Figure 44; RT-qPCR analysis of the indicated miRNAs or their primary transcripts in either mock or shKHSRP 
NMuMg cells. The values of RT-qPCR experiments shown are averages ± SEM of three independent experiments 
performed in triplicate. Statistical significance: *p < 0.01, **p < 0.001 (Student’s t-test).  
 
 
Figure 45; RT-qPCR analysis of the indicated miRNAs in serum-starved NMuMg cells either untreated (/) or treated 
with TGF-β for the indicated times. The values of RT-qPCR experiments shown are averages ± SEM of three 
independent experiments performed in triplicate. Statistical significance: *p < 0.01, **p < 0.001 (Student’s t-test).  
63 
 
 These observations, in addition to the evidence that the expression of miR-192-
5p and miR-194-5p inversely correlates with the metastatic potential of different cancer 
cells (Kim et al., 2011; Geng et al., 2014; Dong et al., 2011; Le et al., 2012), prompted us 
to investigate whether miR-192-5p and miR-194-5p silencing recapitulates gene 
expression changes induced by KHSRP silencing. Expression of anti-miR-192-5p in 
NMuMg cells upregulated Zeb1, Zeb2, as well as Snai1, Iglon5, and Mmp9 expression, while 
it did not affect Fstl1 mRNA levels and even caused downregulation of Fn1, Col6a2, and 
Col12a1 (Figure 46 and Table 2). Conversely, expression of anti-miR-194-5p did not affect 
the expression of EMT factors whose levels are regulated by KHSRP knockdown with 
the exception of a moderate increase in Mmp9 expression (Figure 47 and Table 2). The 
simultaneous silencing of the two miRNAs produced gene expression changes 
overlapping those caused by miR-192-5p silencing alone (data not shown). 
 
 
Figure 46; RT-qPCR analysis of the indicated transcripts in NMuMg cells transfected with either miRNA inhibitor 
negative control or with miRCURY LNA miR-192-5p inhibitor. The values of RT-qPCR experiments shown are 
averages ± SEM of three independent experiments performed in triplicate. Statistical significance: *p < 0.01, **p 
< 0.001 (Student’s t-test).  
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Figure 47; RT-qPCR analysis of the indicated transcripts in NMuMg cells transfected with either miRNA Inhibitor 
negative control or with miRCURY LNA miR-194-5p Inhibitor (anti-miR-194-5p). The values of RT-qPCR 
experiments shown are averages (±SEM) of three independent experiments performed in triplicate. 
 
The above data indicate that neither miR-192-5p or miR-194-5p silencing are 
able to reproduce the whole spectrum of gene expression changes induced by KHSRP 
downregulation. This fact prompted us to hypothesize that KHSRP silencing during 
TGF-β-induced EMT impacts on an additional layer of post-transcriptional gene 
regulation. 
 
5. KHSRP controls alternative splicing of a cohort of pre-
mRNAs involved in cell adhesion and migration 
Considering that KHSRP mainly localizes in the nuclei of NMuMg cells and that 
a role of KHSRP in alternative splicing has already been suggested (Min et al., 1997; Russo 
et al., 2011), we decided to investigate KHSRP potential role in regulatory pre-mRNA 
alternative splicing in NMuMg cells. To this purpose, we applied a sensitive bioinformatic 
approach to analyze our RNA-seq results in order to detect genes that are subject to a 
Differential Exon usage (DEXSeq) (Anders et al., 2012). We identified 763 alternative 
splicing events (log2 fold changes (FC) >|1.2|, BH (Bonferroni-corrected, two-sided 
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hypergeometric test) adjusted p value (adj.pval) < 0.01) involving 518 unique Ensembl 
transcripts that were controlled by KHSRP overexpression. Among the regulated single 
cassette exons, 412 exons were less included while 351 exons were more included upon 
KHSRP overexpression. This ratio is similar to those recently reported for other RBPs in 
a genome-wide analysis of alternative splicing in human cells (Huelga et al., 2012). 
Furthermore, our findings are in line with the recent evidence suggesting that the 
modulation of alternative mRNA splicing plays a causative role in EMT (Cieply & 
Carstens, 2015). Interestingly, GO enrichment analysis revealed that mRNAs whose 
splicing is affected by KHSRP overexpression are mainly involved in biological processes 
such as cytoskeleton organization, cell junction assembly, and regulation of small GTPase-
mediated signal transduction (Figure 48). 
 
 
Figure 48; Gene Ontology (GO) analysis was performed on genes subject to differential exon usage (log2 fold 
changes (FC) > |1.2|, BH adj.pval < 0.01) and the enrichment of the KHSRP-regulated pathways are presented as 
bar graph. 
 
Among these transcripts, we validated by RT-qPCR some of the KHSRP 
controlled cassettes utilizing exon-specific primers and focused exclusively on exons that 
have been proven to generate alternative protein isoforms (according to the Ensembl 
annotation GRCm38.74; http://www.ensembl.org). Representative examples of 
transcripts whose alternative splicing is controlled in a KHSRP-dependent way and have 
subsequently been validated by RT-qPCR analysis are presented in Figure 49. Among them 
Enah gene, whose alternative splicing has been previously implicated in EMT (Warzecha 
et al., 2012), is controlled in a KHSRP-dependent, and we found that KHSRP 
overexpression significantly increased the ratio between the epithelial-type Enah6L 
isoform and the mesenchymal-type Enah6 isoform (Enah6L/Enah6), while KHSRP 
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knockdown significantly impaired the Enah6L/Enah6 ratio mimicking TGF-β effect 
(Figure 50). 
 
 
Figure 49; RT-qPCR analysis performed using exon-specific primers. The results are presented as ratio between 
the expression levels of two alternatively spliced forms of the indicated transcripts (nomenclature of mRNA forms 
derived from alternative splicing is presented according the Ensembl nomenclature). RNA was extracted from 
NMuMg cells infected with either control (AdNull) or KHSRP-expressing adenoviral vectors (AdKHSRP) for 24h 
(left) and from either mock or shKHSRP NMuMg cells (right). 
 
 
Figure 50; Top panel. Schematic of the exon-intron structure (not in scale) of Enah mRNA splice variants 201 and 
004 (ENSMUSG00000022995). The green open box marks the alternatively spliced exons 6 and exon 6L (in red), 
respectively.  
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Bottom panel. RT-qPCR analysis performed using exon-specific primers. The results are presented as ratio 
between the expression levels of Enah exon 6L-including and exon 6-including mRNA isoforms. NMuMg cells were 
infected with either control (AdNull) or KHSRP-expressing adenoviral vectors (AdKHSRP) for 24h and subsequently 
serum-starved and either treated with TGF-β (+) for 24h or untreated (-) (left). Either mock or shKHSRP NMuMg 
cells were serum-starved and then either treated with TGF-β or untreated for 24h (right). 
 
Interestingly, Ribonucleoprotein immunoprecipitation (RIP) analysis followed 
by RNA deep-sequencing performed in NMuMg cells (Briata & Gherzi, unpublished 
data) revealed that KHSRP interacts with a number of pre-mRNAs including those 
encoding CD44 and FGFR2 (Warzecha et al., 2009; Brown et al., 2011) (Figure 51; data 
not shown).  
 
 
Figure 51; Screenshot from Integrative Genomic Viewer output. RIP-seq analysis revealing that KHSRP interacts 
with Cd44 pre-mRNA in NMuMg cells. Arrow points to the region (intron 8-9) used as a probe in EMSA 
experiments. 
 
It has been previously demonstrated that TGF-β treatment induces a shift from 
the epithelial forms of Cd44 and Fgfr2 (Cd44v and Fgfr2 IIIb, respectively) to the 
mesenchymal-specific forms (Cd44s and Fgfr2 IIIc, respectively) that are known to play a 
causative role in EMT (Warzecha et al., 2009; Brown et al., 2011; Cieply & Carstens, 2015). 
Although the log2 fold expression changes in the levels of the alternatively spliced Cd44 
and Fgfr2 cassettes in our differential exon usage analysis of RNA-seq experiments did 
not reach the stringent cutoff value that we initially established, their expression changes 
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were statistically relevant (p.adj< 0.01). We found that KHSRP overexpression 
significantly reduced the ratio between the mesenchymal-type Cd44s and the epithelial-
type Cd44v isoform (Cd44s/Cd44v), meanwhile KHSRP knockdown significantly 
enhanced the Cd44s/Cd44v ratio mimicking TGF-β effect (Figure 52). Similarly, KHSRP 
overexpression favored the inclusion of the Fgfr2 epithelial-specific exon (Fgfr2 IIIb), 
whereas KHSRP silencing favored the inclusion of the mesenchymal cassette (Fgfr2 IIIc) 
in Fgfr2 mRNA (Figure 53). In addition, we show that KHSRP silencing induced a similar 
splicing pattern also in Py2T cells (Figure 54).  
 
 
Figure 52; Top panel. Schematic of the exon-intron structure (not in scale) of Cd44 mRNA splice variants 001 and 
002 (ENSMUSG00000005087). The red open box marks the alternatively spliced variable exons. The bars mark 
the position of primers used to detect, by RT-qPCR, the expression levels of variable (v) and standard (s) exons. 
Bottom panel. RT-qPCR analysis performed using the indicated primers. The results are presented as ratio 
between the expression levels of Cd44s and Cd44v mRNA isoforms. NMuMg cells were cultured as described in 
Figure 50. Arrows in the schematics indicate the transcription direction. 
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Figure 53; Top panel. Schematic of the exon-intron structure (not in scale) of Fgfr2 mRNA splice variants 003 and 
004 (ENSMUSG00000030849). The light blue and red open boxes mark the region including exon IIIb (exon 6 in 
Fgfr2-003) and exon IIIc (exon 8 in Fgfr2-004), respectively.  
Bottom panel. RT-qPCR analysis performed using exon specific primers. The results are presented as ratio 
between the expression levels of exon IIIc- and exon IIIb- including mRNA isoforms. NMuMg cells were cultured 
as described in Figure 50. Arrows in the schematics indicate the transcription direction. 
 
 
Figure 54; RT-qPCR analysis performed using exon-specific primers in either mock or shKHSRP Py2T cells. The 
results are presented as ratio between Cd44s and Cd44v (left) and between Fgfr2 IIIc and Fgfr2 IIIb (right). The 
values of RT-qPCR experiments shown are averages ± SEM of three independent experiments performed in 
triplicate. Statistical significance: **p < 0.001 (Student’s t-test).  
 
Furthermore, when we re-express KHSRP in NMuMg cells that achieved an 
established mesenchymal phenotype through a prolonged treatment with TGF-β (see 
Figure 40 and Figure 42 shown before), we found that KHSRP expression is able to revert 
the TGF-β-induced mesenchymal pattern of Cd44 splicing (Figure 55).  
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Figure 55; RT-qPCR analysis performed using Cd44 exon-specific primers in NMuMg cells serum-starved and 
treated with TGF-β for 7 days and subsequently infected with either AdNull or AdKHSRP and cultured for 3 days 
in the presence of TGF-β. The results are presented as ratio between Cd44s and Cd44v forms. The values of RT-
qPCR experiments shown are averages ± SEM of three independent experiments performed in triplicate. 
Statistical significance: **p < 0.001 (Student’s t-test).  
 
We finally checked if the modulation of miR-27b-3p expression could affect 
Cd44 splicing, and we found that miR-27b-3p overexpression in untreated NMuMg cells 
mimicked both TGF-β effect and KHSRP silencing by favoring mesenchymal-type 
splicing pattern of Cd44 pre-mRNA. Conversely, miR-27b-3p silencing prevented in part 
the TGF-β-mediated exclusion of variable Cd44 exons (Figure 56). 
 
 
Figure 56; RT-qPCR analysis performed using Cd44 exon-specific primers in NMuMg cells transiently transfected 
with either control miRNA mimic (mimic-miR-C) or mimic-miR-27b-3p (left panel) as well as in NMuMg cells 
transiently transfected with either control anti-miRNA (anti-miRC) or anti-miR-27b-3p and treated with TGF-β for 
48h (right panel). The values of RT-qPCR experiments shown are averages ± SEM of three independent 
experiments performed in triplicate. Statistical significance: *p < 0.01, **p < 0.001 (Student’s t-test).  
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In order to identify the Enah, Cd44, and Fgfr2 pre-mRNA regions that are bound 
by KHSRP, we probed anti-KHSRP RIP experiments using intron-specific primers for 
each transcript. These experiments revealed a prominent KHSRP interaction with Enah 
intron 5-6, Cd44 intron 8-9, and Fgfr2 intron 5-6 (Figure 57 and data not shown).  
 
 
Figure 57; Total extracts from NMuMg cells were immunoprecipitated as indicated. RNA was purified from 
immunocomplexes and analyzed by RT-qPCR to detect the indicated pre-mRNAs. The values of RT-qPCR 
experiments shown are averages ± SEM of three independent experiments performed in triplicate. 
 
In agreement with these findings, the Cd44 region spanning i8-9 includes a 
consensus binding motif for KHSRP identified on the basis of HITS-CLIP experiments 
that have been previously performed in the laboratory (Bucci & Bordo, unpublished data). 
In addition, we proved the direct interaction of recombinant KHSRP with this region by 
Electrophoretic mobility shift assay (EMSA) (Figure 58). 
Further, in order to support a direct regulation of Cd44 alternative splicing by 
KHSRP, we transiently expressed a minigene splicing reporter construct including Cd44 
exon v8 (Cd44v8) and its flanking introns in HEK293 cells. Figure 59 shows that KHSRP 
interacts with the minigene in RIP experiments, and that KHSRP knockdown favors exon 
Cd44v8 skipping as evaluated by RT-qPCR using specific primer sets that amplify exon 
Cd44v8-included and Cd44v8-skipped products. 
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Figure 58; EMSA performed to detect the interaction between highly purified recombinant KHSRP (50–300 nM) 
with 32P-labeled RNA corresponding to the 5’ region of Cd44 pre-mRNA intron 8-9 (left panel) as well as the 
interaction between KHSRP (50 nM) with either ARETNF or the inherently stable E3 control RNA as indicated (right 
panel). Representative autoradiograms are displayed. 
 
 
 
Figure 59; Top panel. Total extracts from HEK 293 cells transfected with the Cd44v8 minigene (see Experimental 
Procedures section) were immunoprecipitated as indicated. RNA was purified from immunocomplexes and 
analyzed by RT-qPCR to detect the RNA transcribed from the minigene. 
Mid panel. Schematic of the Cd44v8 minigene construct. The v8 exon and its flanking introns are inserted between 
two constitutive exons. 
Bottom panel. RT-qPCR analysis performed on RNA extracted from HEK293 cells co-transfected with the v8 
minigene and either control siRNA (siControl) or KHSRP-specific siRNA (siKHSRP). 
The values of RT-qPCR experiments shown are averages (±SEM) of three independent experiments performed in 
triplicate. Statistical significance: *p <0.01, **p < 0.001 (Student’s t-test). 
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Altogether, our results indicate that KHSRP influences the alternative splicing 
of a group of pre-mRNAs encoding factors involved in cell-cell and cell-matrix 
interactions as well as in cell migration. 
 
6. KHSRP and hnRNPA1 cooperate to maintain the 
epithelial-type pre-mRNA splicing pattern of Enah, Cd44, and 
Fgfr2 
In the last few years, ribonucleoprotein complexes that involve multiple 
regulatory RBPs able to modulate alternative splicing have been studied in detail (Aparicio 
et al., 2013; Fu & Ares 2014; Cieply & Carstens, 2015).  We wanted to explore whether 
KHSRP associates with other RBPs that are able to control alternative splicing events in 
EMT. It is well known that ESRP1 and ESRP2, here collectively indicated as ESRPs, are 
critical coordinators of an epithelial cell-type-specific splicing program in different cellular 
contexts (Warzecha et al., 2009; Bebee et al., 2015). We found that KHSRP co-
immunoprecipitates with ESRPs in 4T1 mammary gland cells, and that this association is 
RNA-independent because RNase A treatment does non abrogate this association (Figure 
60). Furthermore, KHSRP and ESRPs share similar pre-mRNA targets in 4T1 cells, such 
as Enah, Cd44 and Fgfr2b pre-mRNAs (Figure 61 and data not shown).  
 
 
Figure 60; Co-immunoprecipitation of ESRPs and KHSRP in total extracts from 4T1 mammary gland cells. Cell 
lysates either control-treated or treated with RNAse A (10 µg/ml for 30 minutes at 37°C) were 
immunoprecipitated as indicated and analyzed by immunoblotting using anti-ESRP1/ESRP2 monoclonal antibody. 
The position of molecular mass markers is indicated on the left of each immunoblot. Representative images are 
shown. 
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Figure 61; Total extracts from 4T1 cells were immunoprecipitated as indicated. RNA was purified from 
immunocomplexes and analyzed by RT-qPCR to detect the indicated pre-mRNAs. The values of RT-qPCR 
experiments shown are averages (±SEM) of three independent experiments performed in triplicate. 
 
However, we found that ESRP1 is not expressed in NMuMg cells, while ESRP2 
protein is expressed at low levels (data not shown). Furthermore, we did not detect any 
interaction between KHSRP and ESRP2 in NMuMg cells (Figure 62). Therefore, we 
explored the possibility that KHSRP may associate with a different ribonucleoprotein 
complex able to control alternative splicing events in EMT in NMuMg cells. 
 
 
Figure 62; Co-immunoprecipitation of ESRP2 and KHSRP in total extracts from NMuMg cells. Cell lysates either 
control-treated or treated with RNase A (10 mg/ml for 30 minutes at 37°C) were immunoprecipitated as indicated 
and analyzed by immunoblotting using the indicated antibodies. The position of molecular mass markers is 
indicated on the left of each immunoblot. Representative images are shown. 
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We found that some RBPs that have been implicated in splicing regulation 
during EMT (such as DDX5, DDX17, hnRNPM, and RBFOX2) are either not expressed 
or do not interact with KHSRP in NMuMg cells (data not shown; see the ‘Discussion’ 
section). Conversely, the multifunctional hnRNPA1, a well-known molecular partner of 
KHSRP that has been demonstrated to be implicated in cell-type-specific pre-mRNA 
splicing events, is expressed in NMuMg cells (Ruggiero et al., 2007; Michlewski & Càceres, 
2010; Bonomi et al., 2013; Douablin et al., 2015). Interestingly, whereas the expression of 
KHSRP and other alternative splicing regulators is progressively silenced during EMT in 
NMuMg cells, the levels of hnRNPA1 remain constant during cell exposure to TGF-β 
(Figure 63; data not shown).  
 
 
Figure 63; Immunoblot analysis of total cell extracts from NMuMg cells serum-starved and either treated with 
TGF-β (+) for the indicated times or untreated (-). The indicated antibodies were used. The position of molecular 
mass markers is indicated on the left of each immunoblot. Representative gels are shown.  
 
Co-immunoprecipitation experiments confirmed that KHSRP associates with 
hnRNPA1 in NMuMg cells and that this interaction is abrogated by RNase A treatment 
(Figure 64). This observation prompted us to explore whether KHSRP and hnRNPA1 
interact with the same pre-mRNA regions of Enah, Cd44, and Fgfr2. To this purpose, we 
performed RIP experiments, and we found that KHSRP and hnRNPA1 interact with the 
same regions of these pre-mRNAs (Figure 65).  
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Figure 64; Co-immunoprecipitation of hnRNPA1 and KHSRP in total extracts from NMuMg cells. Cell lysates either 
control-treated or treated with RNase A (10 mg/ml for 30 minutes at 37°C) were immunoprecipitated as indicated 
and analyzed by immunoblotting using the indicated antibodies. The position of molecular mass markers is 
indicated on the left of each immunoblot. Representative gels are shown. 
 
 
Figure 65; Total extracts from NMuMg cells were immunoprecipitated as indicated. RNA was purified from 
immunocomplexes and analyzed by RT-qPCR to detect the indicated pre-mRNAs. The values of RT-qPCR 
experiments shown are averages (±SEM) of three independent experiments performed in triplicate. 
 
Further, EMSA experiments revealed that recombinant hnRNPA1 directly 
interacts with Cd44 intron 8-9 (Figure 66, and see also Figure 58). 
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Figure 66; Electrophoretic mobility shift assays (EMSA) performed to detect the interaction between either 
recombinant GST-hnRNPA1 (50–300 nM) or GST (300 nM) with 32P-labeled RNA corresponding to the 5’ region 
of Cd44 pre-mRNA intron 8-9 (left panel) as well as the interaction between GST-hnRNPA1 (300 nM) with either 
ARE TNF or the inherently stable E3 control RNA as indicated (right panel). Representative autoradiograms are 
displayed. 
 
In order to investigate a possible role of hnRNPA1 in the molecular events that 
are regulated by KHSRP in NMuMg cells, we transiently silenced hnRNPA1 in untreated 
NMuMg cells (Figure 67) and found that its knockdown enhances the expression of a 
subset of EMT factors, such as Fstl1, Mmp9, and Iglon5, whereas it does not affect miR-
192-5p and miR-194-5p expression (Figure 68 and Table 2). 
  
 
Figure 67; Immunoblot analysis of total cell extracts (20 µg) from NMuMg cells transiently transfected with either 
control siRNA (siC) or hnRNPA1-specific siRNAs (sihnRNPA1). The indicated antibodies were used. The position of 
molecular mass markers is indicated on the left of each immunoblot. Representative images are shown. 
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Figure 68; RT-qPCR analysis of the indicated transcripts in either control siRNA (siC) or sihnRNPA1-transfected 
NMuMg cells. The values of RT-qPCR experiments shown are averages (±SEM) of three independent experiments 
performed in triplicate. Statistical significance: **p <0.001 (Student’s t-test). 
 
Further, we demonstrated that hnRNPA1 knockdown, similar to KHSRP 
silencing, promoted the mesenchymal-type exon usage of Enah, Cd44, and Fgfr2 pre-
mRNA (Figure 69). The interaction of hnRNPA1 with these pre-mRNAs is largely 
impaired by TGF-β treatment although the protein continues to be expressed (Figure 70 
and data not shown). 
 
 
Figure 69; RT-qPCR analysis performed using primers specific for the two isoforms of Enah, Cd44, and Fgfr2 
mRNAs, respectively. The results are presented as ratio between the expression levels of the indicated mRNA 
isoforms. NMuMg cells were transfected with either siC or sihnRNPA1 and collected 48h after transfection. The 
values of RT-qPCR experiments shown are averages ± SEM of three independent experiments performed in 
triplicate. Statistical significance: *p < 0.01, **p < 0.001 (Student’s t-test). 
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Figure 70; Total extracts from NMuMg cells serum starved and either treated with TGF-β (+) for 24h or untreated 
(-) were immunoprecipitated as indicated. RNA was purified from immunocomplexes and analyzed by RT-qPCR to 
detect the indicated pre-mRNAs. The values of RT-qPCR experiments shown are averages (±SEM) of three 
independent experiments performed in triplicate. Statistical significance: **p <0.001 (Student’s t-test). 
 
Based on these findings, we investigated whether KHSRP and hnRNPA1 
mutually influence their binding activity to Enah, Cd44, and Fgfr2 pre-mRNAs. Although 
we previously demonstrated that either recombinant protein is able to bind a common 
target RNA in vitro, RIP analyses indicate that the ability of hnRNPA1 to interact with 
Enah, Cd44, and Fgfr2 pre-mRNAs is significantly impaired by KHSRP knockdown, 
whereas the interaction of KHSRP with the same pre-mRNAs is strongly reduced in 
hnRNPA1-knockdown NMuMg cells (Figure 71b).  Finally, we showed that KHSRP re-
expression in shKHSRP NMuMg cells was able to restore the ability of hnRNPA1 to 
interact with Enah, Cd44, and Fgfr2 pre-mRNAs (Figure 72 and data not shown). 
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Figure 71; Upper panel. Total extracts from either mock or shKHSRP NMuMg cells were immunoprecipitated as 
indicated. RNA was purified from immunocomplexes and analyzed by RT-qPCR to detect the indicated transcripts. 
Bottom panel. Total extracts from NMuMg cells transfected with either siC or sihnRNPA1 were 
immunoprecipitated as indicated. RNA was purified from immunocomplexes and analyzed by RT-qPCR to detect 
the indicated transcripts.  
The values of RT-qPCR experiments shown are averages (±SEM) of three independent experiments performed in 
triplicate. Statistical significance: **p <0.001 (Student’s t-test). 
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Figure 72; Total extracts from shKHSRP NMuMg cells, infected with either control (AdNull) or KHSRP-expressing 
(AdKHSRP) adenoviral vectors for 24h and subsequently serum-starved and either treated with TGF-β (+) for 24h 
or untreated (-), were immunoprecipitated as indicated. RNA was purified from immunocomplexes and analyzed 
by RT-qPCR to detect the indicated transcript. The values of RT-qPCR experiments shown are averages ± SEM of 
three independent experiments performed in triplicate. Statistical significance: **p < 0.001 (Student’s t-test). 
 
As a whole, our results suggest that KHSRP and hnRNPA1 are mutually 
necessary for binding to Enah, Cd44, and Fgfr2 pre-mRNAs and for maintaining the 
epithelial-type exon usage of these transcripts in NMuMg cells. 
 
7. Resveratrol prevents TGF-β-induced EMT in mammary 
gland cells 
As a part of a screening that has been carried out in the laboratory where I 
conducted my thesis, aimed at the identification of compounds that can prevent TGF-β-
induced gene expression changes in NMuMg cells, we investigated the effects of 
resveratrol (RESV), a natural polyphenolic compound. To this purpose, we pretreated 
NMuMg cells for 2h with RESV (concentrations ranging from 5 to 150 μM), and then we 
exposed cells to 10 ng/ml TGF-β for 2 days (see also ‘Experimental procedures’ section). The 
expression levels of a representative group of factors crucial to EMT were analyzed by 
RT-qPCR, and we found that RESV (used at a concentration of 75 μM) significantly 
impaired both basal and TGF-β-induced expression of mesenchymal factors (such as Fn1, 
Fstl1, Col6a2, Cdh2, Zeb1, and Col12a1).  Further, RESV enhanced miR-200c expression, 
while reduced miR-155 levels (Figure 73).  
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The observation that RESV prevents the TGF-β-induced expression of 
mesenchymal factors was extended to murine Py2T cells (Figure 74 and data not shown). 
 
Figure 73; RT-qPCR analysis of the indicated transcripts (mRNAs and miRNAs) in NMuMg cells serum starved (2% 
FBS, 16h), pre-treated for 2 h with either RESV (75 μM) or DMSO, and then either treated with TGF-β (10 ng/ml) 
for 48h or left untreated. The values of RT-qPCR experiments shown are averages ±SEM of three independent 
experiments performed in triplicate. Statistical significance: *p<0.01, **p<0.001 (Student's t-test). 
 
 
Figure 74; RT-qPCR analysis of the indicated transcripts in Py2T cells serum-starved (1% FBS, 16h), pre-treated for 
2h with either RESV (75 μM) or DMSO and then either treated with TGF-β (10 ng/ml) for 48h or left untreated. 
The values of RT-qPCR experiments shown are averages ±SEM of three independent experiments performed in 
triplicate. Statistical significance: *p<0.01, **p<0.001 (Student's t-test). 
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A major role of TGF-β in mammary gland cells is to enhance their inherent 
migratory proprieties. In order to investigate whether RESV was able to affect the 
migratory proprieties of NMuMg cells, we performed scratch assays. We observed that 
RESV treatment reduces the gap closure in a time-dependent manner when compared to 
negative control (DMSO)-treated cells (Figure 75).  
 
 
Figure 75; Scratch wound healing assay. NMuMg cells were pre-treated for 2h with either RESV (75 μM) or DMSO 
and then scratch wounds were introduced into confluent monolayers. Cultures were photographed and the width 
of the wound was measured at different intervals of time from 0 to 40h after the scratch was made. 
Representative images are taken at 0 and 40h. Scale bars: 100 μm. The percentage of the wound healed area for 
each culture condition was plotted (right panel). 
 
In addition, RESV treatment was able to revert the expression of EMT makers 
also in NMuMg cells that had achieved a complete mesenchymal phenotype in response 
to a three days TGF-β treatment (Figure 76). 
 
 
Figure 76; Left panel. Schematic of the NMuMg cell treatment.  
Right panel. RT-qPCR analysis of the indicated transcripts in cells treated as summarized in the left panel. The 
values of RT-qPCR experiments shown are averages ±SEM of three independent experiments performed in 
triplicate. Statistical significance: *p<0.01, **p<0.001 (Student's t-test). 
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Altogether these observations indicate that RESV is able to strongly counteract 
the TGF-β-induced EMT phenotype in mammary gland cells. 
  
8. Resveratrol promotes the epithelial-type alternative 
splicing of Cd44, Enah, and Fgfr2 pre-mRNAs in mammary gland 
cells 
One of the major consequences of TGF-β treatment in NMuMg cells is the 
modulation of the alternative splicing of a cohort of pre-mRNAs implicated in EMT 
(including Cd44, Enah, and Fgfr2). Thus, we investigated whether RESV affects the 
alternative splicing of these pre-mRNAs in NMuMg cells. We found that RESV affects 
the alternative splicing of Cd44, Enah, and Fgfr2 pre-mRNAs favoring the inclusion of 
epithelial-type of each of transcript (Cd44s, Enah6L, and Fgfr2 IIIb respectively) thus 
significantly reducing both Cd44s/Cd44v and Fgfr2 IIIc/IIIb ratio, and increasing 
Enah6L/Enah6 ratio (Figure 77). We observed a similar splicing pattern of Cd44 and Enah 
transcript also in PY2T cells (Figure 78). 
 
 
Figure 77; NMuMg cells were serum-starved (2% FBS, 16h), pretreated for 2h with either RESV (75 μM) or DMSO, 
and then either treated with TGF-β (10 ng/ml) for 48h or left untreated. RT-qPCR analysis was performed using 
exon-specific primers of the indicated transcripts. The results are presented as the ratio between the expression 
levels of each isoform as indicated. The values of RT-qPCR experiments shown are averages ±SEM of three 
independent experiments performed in triplicate. Statistical significance: **p<0.001 (Student's t-test). 
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Figure 78; PY2T cells were serum-starved (2% FBS, 16h), pretreated for 2h with either RESV (75 μM) or DMSO, 
and then either treated with TGF-β (10 ng/ml) for 48h or left untreated. RT-qPCR analysis was performed using 
exon-specific primers of the indicated transcripts. The results are presented as the ratio between the expression 
levels of each isoform as indicated. The values of RT-qPCR experiments shown are averages ±SEM of three 
independent experiments performed in triplicate. Statistical significance: **p<0.001 (Student's t-test). 
 
NMuMg cells express seven Cd44 mRNA isoforms as a consequence of 
alternative usage of the ten variable exons (Figure 79). TGF-β treatment induces the 
exclusion of exon 6 of Cd44 and RESV pre-treatment of NMuMg cells prevents TGF-β-
dependent exon 6 skipping (Figure 80).  
 
 
Figure 79; Schematic representation of variable Cd44 exons in NMuMg cells. 
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Figure 80; Left panel. A schematic of Cd44-001 exons 5 to 7. 
Middle panel. RT-PCR analysis of total RNA samples from NMuMg cells that were serum-starved (2% FBS, 16h) 
and either treated with 10 ng/ml TGF-β for 48h or left untreated. 
Right panel. RT-PCR analysis of total RNA samples from NMuMg cells that were serum-starved (2% FBS, 16h), pre-
treated for 2h with either RESV (75 µM) or DMSO, and then either treated with TGF-β (10 ng/ml) for 48h or left 
untreated. 
Representative gels are presented. The ratio between the intensity of bands corresponding to exon 6- excluding 
and exon6- including amplicons (quantitated in three independent experiments) is presented at the bottom of 
each gel. 
 
Further, we observed that RESV treatment of NMuMg cells that achieved an 
overt mesenchymal phenotype (through a three-day treatment with TGF-β) reverted the 
mesenchymal-type splicing pattern of Cd44, Enah, and Fgfr2 pre-mRNAs despite the 
continuous presence of TGF-β (Figure 81). 
 
 
Figure 81; Left panel. Schematic of the NMuMg cell treatment.   
Right panel. RT-qPCR analysis of the expression of the alternative splicing forms of either Cd44, Enah, or Fgfr2 in 
cells treated as summarized in the left panel. The results are presented as the ratio between the expression levels 
of each isoform as indicated. 
The values of RT-qPCR experiments shown are averages ± SEM of three independent experiments performed in 
triplicate. Statistical significance: **p < 0.001 (Student's t-test). 
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It has been reported that RESV limits breast cancer cells proliferation and 
invasiveness (Dandawate et al., 2016). For these reasons, we investigated whether RESV 
is able to increase the expression of epithelial-type versus mesenchymal-type factors in 
transformed mammary gland cells, both murine and human. We found that a 24 hours 
RESV treatment significantly enhanced the expression of epithelial-type cadherin Cdh1, 
while reduced the levels of mesenchymal and invasiveness- related factors such as Fn1, 
Fstl1, and Mmp9 in 4T1, TS/A, and MDA-MB-231 cells (Figure 82 and data not shown). 
In line with these results, scratch wound assays revealed that the gap closure was 
significantly reduced by RESV treatment in 4T1 and TS/A cells when compared to 
control (DMSO-treated) cells suggesting that RESV reduces the migratory propriety of 
these cells (Figure 83 and data not shown).  
 
 
Figure 82; RT-qPCR analysis of the indicated transcripts in 4T1, TS/A, and MDA-MB-231 cell lines. Cells were 
serum-starved and then treated with either RESV (75 μM) or DMSO for 24 h, respectively. The values of RT-qPCR 
experiments shown are averages ± SEM of three independent experiments performed in triplicate. Statistical 
significance: *p < 0.01, **p < 0.001 (Student's t-test). 
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Figure 83; Scratch wound healing assays. 4T1 cells were pre-treated for 2h with either RESV (75 μM) or DMSO 
and then scratch wounds were introduced into confluent monolayers. Cultures were photographed and the width 
of the wound was measured at different intervals of time from 0 to 40 h after the scratch was made. 
Representative images at 0 and 40h are shown (Left panel). Scale bars: 100 μm. The percentage of the wound 
healed area for each culture condition was plotted (Right panel). 
 
Recent experimental evidence connected the molecular program of alternative 
splicing regulation with the occurrence of metastasis in patients (Xu et al., 2014; Matsuda 
et al., 2012; Oudin et al., 2016). For these reasons, we decided to investigate whether the 
ability of RESV to affect the alternative exon usage of Cd44 and Enah in transformed 
mammary gland cell lines. Cultures were treated with RESV for 24h and the expression 
of epithelial- and mesenchymal- type splicing variants of Cd44 and Enah pre-mRNAs was 
quantitated by RT-qPCR analysis. We found that RESV favored the inclusion of the 
respective epithelial-type splicing variants of Cd44 and Enah also in 4T1, TS/A, and 
MDA-MB-231 cells (Figure 84). 
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Figure 84; RT-qPCR analysis of the alternative isoforms of Cd44 and Enah in 4 T1, TS/A, and MDA-MB-231 cells. 
Cells were serum-starved and then treated with either RESV (75 μM) or DMSO for 24h, respectively. The results 
are presented as the ratio between the expression levels of each isoform as indicated. The values of RT-qPCR 
experiments shown are averages ± SEM of three independent experiments performed in triplicate. Statistical 
significance: *p < 0.01, **p < 0.001 (Student's t-test). 
 
Altogether our data indicate that RESV affects the alternative exon usage of pre-
mRNAs that encode factors crucial to adhesion and migration in both immortalized and 
transformed mammary gland cells. 
 
9. Resveratrol upregulates KHSRP and hnRNPA1 
expression to favor the epithelial-type alternative splicing of Cd44 
pre-mRNA in mammary gland cells 
Data presented in the first part of the ‘Results’ section indicate that TGF-β-
dependent KHSRP down-regulation is required to favor the mesenchymal-type splicing 
pattern of Cd44, Enah, Fgfr2, and other pre-mRNAs during EMT. Consequently, we 
hypothesized that RESV may affect the alternative splicing of select pre-mRNAs by 
influencing KHSRP expression. Indeed, RESV treatment increases the expression of 
KHSRP in untreated NMuMg cells and restored, in part, its levels in TGF-β-treated cells 
(Figure 85).  
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Figure 85; Immunoblot analysis of total cell extracts from NMuMg cells serum-starved and pre-treated for 2h with 
either RESV (75 μM) or DMSO and then either treated with TGF-β for 48h or left untreated. The indicated 
antibodies were used. Bands corresponding to anti-KHSRP and anti-ACTB immunoreactivity were quantitated in 
three independents immunoblots (using ImageJ 1.49 software) and the ratio between their intensities is 
presented in Arbitrary Units. 
 
In agreement with our observation that miR-27b-3p causes KHSRP down-
regulation, we found that RESV prevented TGF-β-induced miR-27b-3p up-regulation 
thus suggesting that RESV affects KHSRP expression at post-transcriptional level (Figure 
86). Further support to our hypothesis that RESV influences alternative splicing by 
regulating KHSRP levels was provided by the evidence that RESV treatment controls the 
alternative isoform usage of a group of pre-mRNAs that are splicing targets of KHSRP 
(Figure 87 and see above). 
 
 
Figure 86; RT-qPCR analysis of miR-27b-3p in NMuMg cells serum-starved (2% FBS, 16h), pre-treated for 2h with 
either RESV (75 µM) or DMSO and then either treated with TGF-β (10 ng/ml) for 48h or left untreated. The values 
of RT-qPCR experiments shown are averages ± SEM of three independent experiments performed in triplicate. 
Statistical significance: **p < 0.001 (Student's t-test). 
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Figure 87; RT-qPCR analysis performed in NMuMg cells serum-starved (2% FBS, 16h), and treated with either RESV 
(75 µM) or DMSO for 24h using exon-specific primers. The results are presented as ratio between the expression 
levels of two alternatively spliced forms of the indicated transcripts (nomenclature of mRNA forms derived from 
alternative splicing is presented according to Ensembl). 
 
In order to verify our hypothesis, we analyzed the response to RESV in KHSRP-
silenced mammary gland cells compared to mock-silenced cells. KHSRP silencing 
significantly limited, but failed to abrogate, the RESV-dependent reduction of the 
Cd44s/Cd44v ratio in NMuMg cells (Figure 88). Similar effect of KHSRP silencing was 
obtained in 4T1 cells (Figure 89).  
 
 
Figure 88; Either mock or shKHSRP NMuMg cells were serum-starved and pre-treated for 2h with either RESV (75 
μM) or DMSO and then treated with TGF-β (+) for 4h. The expression levels of Cd44v and Cd44s were measured 
by RT-qPCR and presented as ratio between the expression levels of Cd44s and Cd44v forms. 
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Figure 89; Left panel. Immunoblot analysis of total cell extracts from either mock or shKHSRP 4T1 cells as marked. 
The indicated antibodies were used.  
Right panel. Either mock or shKHSRP 4T1 cells were treated for 24h with either RESV (75 µM) or DMSO. The 
expression levels of Cd44v and Cd44s were measured by RT-qPCR and presented as ratio between Cd44s and 
Cd44v forms. 
 
 
Even though the ability of RESV to up-regulate the expression of the small 
residual amount of KHSRP still present in shKHSRP cells (Figure 90 and data not shown) 
could explain, at least in part, the incomplete effect of KHSRP silencing, our results 
prompted us to investigate additional mechanisms for the effect of RESV on Cd44 
alternative splicing modulation.  
 
 
Figure 90; Immunoblot analysis of total cell extracts from shKHSRP NMuMg treated with either RESV (75 µM) or 
DMSO for 48h. The indicated antibodies were used. Bands corresponding to anti-KHSRP and anti-ACTB immune-
reactivity were quantitated in three independents immunoblot (using ImageJ 1.49 software) and the ratio 
between their intensities is presented in Arbitrary Units. 
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Considering that KHSRP is able to interact with hnRNPA1 to form a 
ribonucleoprotein complex that regulates alternative exon usage in NMuMg cells (see 
above), we explored the possibility that RESV may affect the expression of hnRNPA1. 
Indeed, we found that RESV enhances hnRNPA1, similar to KHSRP expression, in both 
NMuMg and 4T1 cells (Figure 91).  
 
 
 
Figure 91; Left panel. Immunoblot analysis of total cell extracts from NMuMg cells serum-starved (2% FBS, 16h), 
pre-treated for 2h with either RESV (75 μM) or DMSO and then treated with TGF-β for 48h. 
Right panel. Immunoblot analysis of total cell extracts from 4 T1 cells treated for 24 h with either RESV (75 μM) 
or DMSO. The indicated antibodies were used. Bands were quantitated in three independents immunoblot (using 
ImageJ 1.49 software) and the ratio between the intensity of either KHSRP or hnRNPA1 immunoreactivity and 
ACTB immunoreactivity is presented in Arbitrary Units.  
 
To further support our hypothesis, we stably silenced hnRNPA1 in 4T1 cells 
and we analyzed the effects of RESV on Cd44 pre-mRNA alternative splicing. We found 
that hnRNPA1 silencing significantly limited the RESV-dependent reduction of the 
Cd44s/Cd44v ratio although failed to completely prevent the RESV-induced epithelial-
type Cd44 alternative splicing (Figure 92).  
Thus, considering that the individual silencing of either KHSRP or hnRNPA1 
failed to completely abrogate RESV effect on Cd44 alternative splicing, we decided to 
simultaneously silence both KHSRP and hnRNPA1 in 4T1 cells and to quantitate the 
Cd44 pre-mRNA alternative splicing isoforms. The double stable silencing of KHSRP 
and hnRNPA1 almost completely prevented the induction of the epithelial-type Cd44 
exon usage by RESV (Figure 93). 
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Figure 92; Left panel. Immunoblot analysis of total cell extracts from either mock or shhnRNPA1 4T1 cells. The 
indicated antibodies were used. The position of molecular mass markers is indicated on the left of each 
immunoblot. 
Right panel. Either mock or shhnRNPA1 4 T1 cells were treated for 24h with either RESV (75 μM) or DMSO. The 
expression levels of Cd44v and Cd44s were measured by RT-qPCR and presented as ratio between Cd44s and 
Cd44v forms. The values of RT-qPCR experiments shown are averages (±SEM) of three independent experiments 
performed in triplicate. Statistical significance: **p < 0.001 (Student's t-test). 
 
 
Figure 93; Left panel. Immunoblot analysis of total cell extracts from either mock or shKHSRP/shhnRNPA1 4T1 
cells. The indicated antibodies were used. The position of molecular mass markers is indicated on the left of each 
immunoblot. 
Right panel. Either mock or shKHSRP/shhnRNPA1 4T1 cells were treated for 24h with either RESV (75 μM) or 
DMSO. The expression levels of Cd44v and Cd44s were measured by RT-qPCR and presented as ratio between 
Cd44s and Cd44v forms. The values of RT-qPCR experiments shown are averages (±SEM) of three independent 
experiments performed in triplicate. Statistical significance: **p < 0.001 (Student's t-test). 
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In order to strengthen our findings, we transiently expressed the minigene 
splicing reporter construct including Cd44v8 and its flanking introns in HEK-293 cells in 
which RESV is able to modulate the alternative splicing of endogenous Cd44 pre-mRNA 
(Figure 94).  We found that RESV significantly decreased the skipped/included exon 
Cd44v8 ratio as evaluated by RT-qPCR using specific primer sets that amplify exon 
Cd44v8-included and Cd44v8-skipped products (Figure 95).  
 
 
Figure 94; HEK-293 cells were treated with either DMSO or RESV (75 μM) (as indicated) for 24h. The expression 
levels of Cd44v and Cd44s were measured by RT-qPCR and presented as ratio between the expression levels of 
the two forms as indicated. The values of RT-qPCR experiments shown are averages (±SEM) of three independent 
experiments performed in triplicate. Statistical significance: **p < 0.001 (Student's t-test). 
 
 
Figure 95; Upper panel. Schematic of the Cd44v8 minigene construct. The Cd44v8 exon and its flanking introns 
are inserted between two constitutive exons.  
Lower panel. RT-qPCR analysis performed on RNA extracted from HEK-293 cells co-transfected with the Cd44v8 
minigene and treated with either DMSO or RESV (75 μM) (as indicated) for 24h. The values of RT-qPCR 
experiments shown are averages (±SEM) of three independent experiments performed in triplicate. Statistical 
significance: **p < 0.001 (Student's t-test). 
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Agarose gel electrophoresis of end-point RT-qPCR reactions shows a reduction 
of the exon Cd44v8-skipped product and a strong increase of the exon Cd44v8-included 
PCR product (Figure 96). Finally, silencing of both KHSRP and hnRNPA1 almost 
completely hindered the effect of RESV on the splicing pattern of Cd44v8 minigene in 
HEK-293 cells (Figure 97). 
 
 
Figure 96; Agarose gel electrophoresis of end-point RT-qPCR reactions as described in Figure 94. M1 and M2 
correspond to two distinct molecular weight markers. A representative gel is shown. 
 
 
Figure 97; RT-qPCR analysis performed on RNA extracted from HEK-293 cells co-transfected with the Cd44v8 
minigene and either control siRNA (siControl) or KHSRP-specific siRNA (siKHSRP) together with hnRNPA1-specific 
siRNA (sihnRNPA1). 24h after transfection cells were treated with either DMSO or RESV (75 μM) (as indicated) for 
24h. The values of RT-qPCR experiments shown are averages (±SEM) of three independent experiments 
performed in triplicate. Statistical significance: *p < 0.01, **p < 0.001 (Student's t-test). 
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As a whole our data indicate that RESV affects Cd44 alternative splicing by 
upregulating the expression of KHSRP and hnRNPA1 and that the combined silencing 
of these two RBPs prevents its action. 
 
 
Table 2; Synopsis of the expression changes, quantitated by RT-qPCR analysis, of EMT markers under distinct 
experimental conditions. The values of RT-qPCR experiments shown are averages of at least three independent 
experiments performed in triplicate. Values indicated in bold are statistically different, p-value at least < 0.01, 
Student’s t-test. ‘Na’ is for not assayed. 
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Discussion 
 
 
The major finding of the experimental work described in this thesis is that TGF-
β-dependent early induction of miR-27b-3p silences the multifunctional single-strand 
nucleic acid binding protein KHSRP in non-transformed mammary gland cells. This 
silencing produces a vast rearrangement of the transcriptome and contributes to EMT. 
KHSRP silencing impairs maturation of miR-192-5p, with the consequent upregulation 
of a subset of EMT factors, and favors alternative exon usage of genes involved in cell 
adhesion and migration (Figure 98). 
 
 
Figure 98; Schematic pathway of results reported here. 
 
Previous studies conducted in the laboratory and current experiments suggest 
that ligands belonging to the TGF-β family need to overcome KHSRP function in order 
to orient cell differentiation decisions. This is achieved either through SMAD-mediated 
inhibition of KHSRP activity that leads to a maturation blockade of pro-myogenic 
miRNAs (Pasero et al, 2012) or through abrogation of KHSRP expression, as in the case 
of this study. 
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In my thesis, I report that miR-27b-3p is a component of the TGF-β signaling 
pathway that contributes to the EMT process through KHSRP silencing. A miRNA-
mediated downregulation of KHSRP expression by TGF-β has also been reported by 
Sundaram and colleagues showing that miR-181a-dependent KHSRP silencing leads to a 
switch between maturation from precursors of the primate-specific miR-198 and 
expression of FSTL1, a glycoprotein produced mainly by cells of mesenchymal origin, 
during wound healing (Sundaram et al, 2013). The fact that in our model KHSRP silencing 
is achieved through a distinct miRNA and results in a different cascade of events put 
forward the idea that TGF-β family members operate in a variety of ways to silence 
KHSRP expression/function and emphasize the importance of the ‘‘TGF-β/KHSRP 
antagonism’’ as a hub during TGF-β-family-member-driven cell differentiation.  
One of the more extensively investigated functions of KHSRP is to promote 
miRNA maturation from precursors (Briata et al., 2016). Although TGF-β-dependent 
KHSRP silencing controls the expression of miRNAs previously implicated in EMT 
(Zhang et al, 2014; data not shown), we decided to analyze in detail the miR-192-5p 
function because its maturation from primary transcripts is directly controlled by KHSRP. 
However, the evidence that miR-192-5p silencing fails to reproduce the whole spectrum 
of gene expression changes caused by KHSRP silencing prompted us to explore the 
impact of KHSRP on an additional layer of regulation. 
Despite the fact that biochemical experiments uncovered KHSRP involvement 
in alternative splicing 20 years ago (Min et al, 1997), the data that I present in my thesis 
show the role of KHSRP-modulated exon usage in a cell trans-differentiation model. 
Regulation of gene expression by alternative splicing was the first post-transcriptional 
mechanism linked to EMT (Savagner et al, 1994) and, indeed, it can impact on all the 
events described as ‘‘hallmarks of cancer’’. RBPs able to control alternative splicing have 
emerged as critical regulators of EMT in the last few years. Huelga and colleagues 
demonstrated on a genomic scale that RBPs coordinately regulate hundreds of pre-
mRNA alternative splicing events forming dynamically regulated complexes (Huelga et al, 
2012). ESRPs have been reported as epithelial-specific splicing regulators implicated in 
EMT-associated alternative exon usage (Warzecha et al., 2009; Bebee et al., 2015). Here, 
we report on the interaction between KHSRP and ESRPs in cells that co-express the 
three proteins. However, ESRP1 is not expressed while ESRP2 protein levels are low in 
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NMuMg cells (data not shown). Similarly, Lin28, a factor recently reported as a modulator 
of alternative splicing in breast cancer cells (Yang et al, 2015), is not expressed in NMuMg 
cells (data not shown). RNA helicases DDX5 and DDX17 have been implicated at 
different transcriptional and post-transcriptional levels in EMT and their expression is 
silenced by TGF-β treatment (Dardenne et al, 2014). However, their knockdown failed 
to affect the expression of EMT factors and to influence the KHSRP-dependent 
alternative splicing events in NMuMg cells (Briata & Gherzi, unpublished observation). 
Xu and colleagues have recently demonstrated that hnRNPM, competing with ESRP1, 
favors the mesenchymal-type alternative splicing of Cd44 and other pre-mRNAs and 
promotes breast cancer metastasis by activating EMT (Xu et al, 2014). Also in this case, 
the fact that ESRP1 is absent and hnRNPM expression is silenced in a time-dependent 
manner in response to TGF-β in NMuMg cells (data not shown) makes it unlikely that 
this regulatory network is operative in our model. RBFOX2 is another important 
alternative splicing regulator in different tissues (Shapiro et al, 2011; Braeutigam et al, 
2014; Damianov et al, 2016). However, a comparison of RBFOX2 target transcripts 
described elsewhere (Braeutigam et al, 2014) with the results of our analysis failed to reveal 
any overlap. 
hnRNPA1 is a ubiquitous and predominantly nuclear RBP implicated in a 
number of cellular processes, including pre-mRNA splicing regulation (Matter et al, 2000; 
He & Smith, 2009; Bonomi et al, 2013; Douablin et al, 2015), and we and others have 
previously observed that KHSRP and hnRNPA1 associate in different cell types 
(Ruggiero et al, 2007; Michlewski & Càceres, 2010). Michlewski and Càceres 
demonstrated that the two proteins show similar binding preferences to RNA sequences 
(Michlewski & Càceres, 2010), and our in vitro binding data indicate that KHSRP and 
hnRNPA1 directly bind to a region located in the intron 8-9 of Cd44 pre-mRNA. 
Interestingly, this sequence includes two ‘GGG’ triplets, a preferred binding site for both 
KHSRP (Trabucchi et al, 2009), and hnRNPA1 (Michlewski & Càceres, 2010). On the 
basis of our RIP analyses, it is tempting to speculate that KHSRP and hnRNPA1 form a 
complex with Enah, Cd44, and Fgfr2 pre-mRNAs, respectively, and that each protein is 
required to allow the other to interact with these target transcripts. TGF-β-induced 
KHSRP downregulation causes a destabilization of the RNA/protein complex and 
hnRNPA1, although still present, is unable to interact with Enah, Cd44, and Fgfr2 pre-
mRNAs. 
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Two recent reports suggested a major role for EMT in chemoresistance, and the 
analysis of our RNA-seq data showed that KHSRP regulates the expression of a relevant 
number of transcripts involved in drug transport and metabolism (Fischer et al, 2015; 
Zheng et al, 2015) (Table 3). This allows us to hypothesize that, in addition to affecting 
cell adhesion and migration, KHSRP could influence the expression of factors relevant 
to other crucial EMT-driven events.  
 
 
Table 3; Regulation by KHSRP of the expression levels of transcripts involved in drug transport and metabolism 
described in Fischer et al., 2015 and in Zheng et al., 2015. 
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NMuMg cells used in our studies are representative of an early stage of 
mammary transformation and respond to TGF-β-inducing KHSRP silencing and, as a 
consequence, a variety of EMT-like phenotypic changes. In more advanced stages of 
transformation, cells become independent of TGF-β signaling and TGF-β treatment fails 
to silence KHSRP expression. This is in agreement with the evidence that human tumors 
acquire loss-of-function mutations in genes encoding TGF-β receptors or SMAD 
proteins (Pardali & Moustakas, 2007). We speculate that KHSRP silencing is required in 
early stages of transformation in order to enable TGF-β to initiate cell trans-
differentiation process. Our contribution to the understanding of how TGF-β-modulated 
KHSRP expression affects distinct layers of post-transcriptional gene control provides 
insights in the biology of epithelial cells that are poised to undergo a transition toward a 
mesenchymal phenotype. 
In addition to greater chemoresistance, cells that have undergone EMT increase 
stem-like traits in vitro (Mani et al., 2008; Morel et al., 2008) and in vivo (Guo et al., 2012). 
This observation raised the hope that targeting EMT could eradicate the rare self-
renewing and multipotent ‘cancer stem cells’ (CSCs) that persist following conventional 
chemotherapy. Several candidate EMT-reversing agents are already available clinically and 
it has been proposed to use these “EMT-reversing” inhibitors in combination with other 
drugs to generate synthetic lethality. Along these lines, small chemical inhibitors of various 
signaling pathway are currently being used in clinical trials for their anti-EMT activities. 
Our strategy was to investigate the potential of a natural compound, the resveratrol 
(RESV), previously proved to affect KHSRP function to revert EMT-associated gene 
expression changes. 
We show that RESV limits EMT in mammary gland cells by affecting the 
alternative splicing pattern of pre-mRNAs related to cell adhesion and motility including 
Cd44, Fgfr2, and Enah. Our data indicate that RESV causes a shift from the mesenchymal-
specific forms of the encoded factors to the respective epithelial forms in both 
immortalized and transformed mammary gland cells by modulating the expression of 
KHSRP and hnRNPA1 (Figure 99). 
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Figure 99; Schematic pathway of results reported here. 
 
Markus and colleagues previously reported that RESV can affect the alternative 
splicing of transfected minigenes suggesting that this might be due to enhanced 
expression of a group RBPs (Markus et al, 2011). Our data demonstrate that RESV 
modulates the alternative splicing of endogenous pre-mRNAs that exert a crucial role in 
EMT and that RESV-dependent upregulation of KHSRP and hnRNPA1 is critical to 
enhance the epithelial-type exon usage of Cd44 pre-mRNA in mammary gland cells.  
Using a target-fishing approach with RESV as a bait and peripheral blood 
mononuclear cells as target source, Pautz and coworkers have proved that RESV directly 
interacts with KHSRP and modulates its mRNA decay promoting activity thus resulting 
in down-regulation of pro-inflammatory cytokine expression in colon cancer cells 
(Bollmann et al, 2014). In their report, authors show that RESV reduces the MAPK14-
dependent threonine phosphorylation that has inhibitory effects on KHSRP mRNA 
decay-promoting function (Bollmann et al, 2014; Briata et al, 2005). It is well known that 
KHSRP can operate on multiple layers of post-transcriptional control in response to 
distinct stimuli depending on the cellular context (Briata et al, 2013; Briata et al, 2016). In 
the laboratory where I conducted my thesis as well as in other laboratories, it has been 
demonstrated that various cellular effectors influence KHSRP function through 
phosphorylation and/or cellular localization (Briata et al, 2013; Briata et al, 2016). 
However, in this thesis we demonstrate that KHSRP down-regulation is able to reshape 
the transcriptome preventing, in part, TGF-β-induced EMT in mammary gland cells. 
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Moreover, RESV seems to exert its effect regulating KHSRP levels even though our 
experiments cannot exclude a RESV-induced modulation of KHSRP function. It is 
interesting to note that here we observed that several breast cancer cell lines, including 
4T1, display a limited EMT response to TGF-β and that TGF-β fails to reduce KHSRP 
levels. Our current data indicate that RESV up-regulates KHSRP expression also in 4T1 
cells and that KHSRP silencing strongly influence alternative splicing in these cells. This 
reinforces the idea that RESV controls KHSRP function through modulation of its 
expression levels, at least in mammary gland cells. 
Recent evidence demonstrated that several RBPs coordinately regulate hundreds 
of pre-mRNA alternative splicing events forming dynamically regulated 
ribonucleoprotein complexes (Huelga et al, 2012; Fu & Ares, 2014). Thus, although in 
our cellular models RESV activity on Cd44 pre-mRNA splicing is abrogated by the 
combined silencing of KHSRP and hnRNPA1, it is very likely that RESV may target 
distinct ribonucleoprotein complexes to modulate pre-mRNA alternative splicing in other 
cellular contexts. 
The importance of alternative splicing in various diseases (Cieply & Carstens, 
2015) makes the identification of non-toxic compounds that inhibit certain splicing events 
of notable interest. Indeed, RESV ability to modulate the function and expression of 
different RBPs including KHSRP and hnRNPA1 might account for a part of the wide 
range of beneficial effects shown by the compound. However, RESV ability to affect 
different targets at different levels raises a specificity issue and makes compelling the 
necessity to investigate the whole spectrum of RESV potentialities at the molecular level. 
Altogether, data presented in my thesis underscore the ability of KHSRP to exert 
a coordinate regulation of distinct post-transcriptional events in gene expression control 
during EMT. KHSRP controls pre-mRNA alternative splicing, unstable miRNA decay, 
and maturation of miRNAs from their precursors, depending on its cellular localization 
and on its cellular partners. Our findings point to KHSRP as a potential target for 
bioactive compounds that can be exploited to manipulate gene expression in cells 
undergoing tumor progression. 
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